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Abstract
Of the minimal information describing drug dialyzability, the majority was obtained prior to
modern hemodialysis membranes. This study characterized the dialyzability of the most
commonly prescribed beta blockers in patients undergoing high-flux hemodialysis. Eight
subjects were recruited to a pharmacokinetic, 4-way crossover trial. Drug concentrations
were measured using mass spectrometry and dialyzability determined by the arterial-venous
difference and recovery clearance methods. A provincial-wide retrospective cohort study was
designed to determine the effect of dialyzability on adverse clinical outcomes. Beta blocker
efficacy can be hindered if substantial clearance occurs during dialysis. Our results
demonstrate atenolol and metoprolol are extensively cleared during hemodialysis, while
carvedilol displays low dialyzability. Although bisoprolol was previously considered to be
minimally dialyzed, we now demonstrate moderate dialyzability. This highlights the
importance of conducting dialyzability studies. With recent findings suggesting heightened
mortality risk in hemodialysis patients prescribed highly dialyzed beta blockers, dialyzability
data is critical to optimize pharmacotherapy.
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INTRODUCTION
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1.1 Renal Physiology
Our understanding of renal physiology continues to advance at an accelerated
rate, especially due to global trends of a growing renal impairment population. Yet, the
basic lessons learned from early measurements and elegant studies still provide the
foundation for researchers today. The overarching role of the kidneys to maintain
physiological homeostasis is now empirically recognized. Despite only weighing 150
grams each, kidneys receive more than 20% of the cardiac output supplied by the heart
(Suzuki and Saruta, 2004). This highlights the responsibility of the kidneys to filter blood
and remove excess organic molecules, regulate electrolyte balance, and maintain body
fluid volume. All these functions are interrelated to the crucial role of the renal system in
regulating long-term systemic blood pressure (Suzuki and Saruta, 2004).
The renin-angiotensin aldosterone system (RAAS) utilizes a negative feedback
pathway to control hormone production, which subsequently modulates blood pressure
(Gross et al., 1964). In short, insufficient levels of sodium in circulation can be sensed by
macula densa cells of the kidneys and lead to the production of renin by juxtaglomerular
cells. Angiotensinogen—a plasma protein constitutively produced by the liver—is
converted into angiotensin I by renin which serves as the rate limiting enzymatic step in
RAAS. Upon reaching the lungs, angiotensin I is further transformed into angiotensin II
by angiotensin-converting enzyme (ACE). Angiotensin II is a potent vaso-active
hormone that raises blood pressure through direct widespread vasoconstriction. This
hormone can also indirectly regulate blood pressure by altering sodium reabsorption and
promoting aldosterone secretion. Aldosterone itself can lead to further increase in blood
pressure by means of water and sodium retention. It comes as no surprise that
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inappropriate activation of RAAS is recognized as one of the main mechanisms for
hypertension progression (Campese and Park, 2006). Hence, many pharmacological
compounds developed in the last 40 years have utilized this homeostatic system to
combat hypertension and cardiovascular disease. ACE inhibitors and angiotensin receptor
blockers (ARBs) have now become first-line treatments for many patients today,
including those with renal impairment (Becker et al., 2012).

1.2 Overview of Chronic Kidney Disease
1.2.1

Prevalence, Detection, and Progression
Similar to other economically developed nations, Canada is defined by its ageing

population. Such a characterization has profound implications on the health care system,
requiring greater emphasis on optimizing treatment for chronic diseases (Wiener and
Tilly, 2002; Lefebvre and Goomar, 2005). In particular, chronic kidney disease (CKD)
has quickly developed into one of the largest national health concerns in recent times.
Approximately 12.5% of adults in Canada are living with some form of CKD, which is
similarly observed in the USA’s population (13.1%) (Coresh et al., 2007; Arora et al.,
2013). Focusing specifically on patients over the age of 60, the prevalence of CKD is
markedly higher with estimates surpassing 30% in Canada and the USA (Arora et al.,
2013; Saran et al., 2016). In both these nations, CKD affects a greater proportion of the
population as compared to Europe (4.7–8.1 %), Asia (2.5–6.8 %) and Australia (11.2%)
(Zhang and Rothenbacher, 2008). These statistics emphasize the importance of early
disease recognition in hopes of preventing CKD progression in North America.
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CKD is an irreversible condition that is typically characterized by three or more
months of renal abnormalities leading to a progressive decline in estimated glomerular
filtration rate (eGFR) (Stevens et al., 2013). With a lower GFR, serum urea and
creatinine levels in CKD patients begin to elevate and serve as estimates of renal function
(Smith et al., 2006). Outlined by the severity in kidney dysfunction and classified based
on eGFR measurements, patients advance through five successive stages of CKD. The
most commonly used method to assess patient eGFR is the Modification of Diet in Renal
Disease (MDRD) Study equation, which takes into consideration serum creatinine, age,
gender and ethnicity of patients (Levey et al., 1999). However, for patients who exhibit
an actual measured GFR value greater than 60 mL/min/1.73 m2, this equation often leads
to an over diagnosis of CKD severity due to its frequent underestimation of eGFR
(Stevens et al., 2007). Consequently, the National Kidney Foundation has recommended
the use of the CKD-EPI method to assess kidney function based on its improved accuracy
to correctly categorize patients into their appropriate stage of CKD (Stevens et al., 2010;
Stevens et al., 2011). This estimating equation considers the same variables as the
MDRD method and defines normal kidney function as having an eGFR of at least 90
mL/min/1.73m2 with no albuminuria or structural abnormalities (KDIGO CKD Work
Group, 2013). Since minimal decline in GFR is observed for patients in early stages of
CKD, the albumin to creatinine ratio (ACR) is analyzed in urine samples to assess and
diagnose any initial deterioration in renal function. Albumin detection in urine suggests
increased glomerular permeability as a result of kidney injury. Patients are categorized
into one of the three classifications of ACR: normal (< 30 mg/g creatinine), moderately
increased (30–300 mg/g creatinine) or severely increased (> 300 mg/g creatinine). In
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clinical practice, combining both eGFR and ACR allows physicians to determine an
individual’s risk for CKD progression (Table 1.1).
Patients with CKD stage 1 or 2 exhibit normal (≥ 90 mL/min/1.73 m 2) or
marginally decreased (60–89 mL/min/1.73 m2) eGFR with abnormalities in kidney
function observed through elevated ACR. Patients with stage 3 CKD (eGFR of 30–59
mL/min/1.73 m2) account for more than half of the patient population (Coresh et al.,
2007). During this stage, accumulation of uremic toxins as a consequence of hindered
renal clearance causes the development of uremic syndrome and other comorbidities. The
condition of uremia causes physiological changes that affect cognitive function, alter
basal metabolic rate, disturb hormonal regulation, and lead to overall imbalances in
homeostasis (Depner, 2001; Meyer and Hostetter, 2007). As a result, a substantial
increase in risk of death, cardiovascular events and hospitalizations is observed for stage
3 CKD patients with an eGFR of less than 45 mL/min/1.73 m2 (Go et al., 2004). For
some patients, continued decline of eGFR and renal function will ultimately lead to stage
5 CKD (eGFR < 15 mL/min/1.73 m2), also known as end-stage renal disease (ESRD). If
left untreated, the severity of comorbidities and complications amongst ESRD patients
result in a nearly 600 percent increase in risk of mortality as compared to CKD patients in
stage 1 or 2 (Go et al., 2004). Although preventing disease progression is an important
aspect of managing renal insufficiency, more effective treatment plans to address
comorbidities and complications are needed to improve the prognosis of CKD patients.
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Table 1.1. Grid of eGFR and albuminuria levels reflecting risk for CKD progression by intensity
of colouring (green, yellow, orange and red).

eGFR Categories (mL/min/1.73m2)

Albuminuria Categories

CKD
Stage

eGFR

Description

1

≥ 90

Normal

2

60–89

Mild ↓GFR

3

30–59

Moderate
↓GFR

4

15–29

Severe
↓GFR

5

<15

Kidney
Failure

Adapted from KDIGO, 2013.

Normal

Moderately
Increased

Severely
Increased

ACR < 30 mg/g
creatinine

ACR 30–300
mg/g creatinine

ACR > 300
mg/g creatinine

Low Risk

Moderate Risk

High Risk

High Risk
Very High Risk
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1.3 Causes and Complications in Chronic Kidney Disease
1.3.1

Diabetes in CKD
Diabetes mellitus (henceforth referred to as diabetes) is the primary cause of CKD

and accounts for 36% of ESRD patients in Canada (Canadian Institute for Health
Information, 2016). With trends suggesting a continued growth in the global burden of
diabetes and nearly 5 million Canadians projected to be diagnosed with the condition by
2025, the proportion of CKD attributable to diabetes will inevitably rise (Guariguata et
al., 2014; Canadian Diabetes Association, 2015). Accordingly, healthcare professionals
can attempt to delay CKD progression by ensuring early detection and creating
appropriate treatment plans for diabetic patients. In type 2 diabetes, 39% of patients
demonstrate microalbuminuria (ACR of 30–300mg/g creatinine) and 10% are diagnosed
with macroalbuminuria (ACR greater than 300 mg/g creatinine)—both of which are
powerful risk factors for diabetic nephropathy and cardiovascular disease (Ljungman et
al., 1996; Parving et al., 2006; Chronic Kidney Disease Prognosis Consortium et al.,
2010). An additional measure to ascertain diabetes severity is the level of glycated
hemoglobin (HbA1c) found in patient blood, which estimates the average plasma glucose
concentration over the previous three months. Hyperglycemia is the most notable feature
of diabetes and the underlying determinant for vascular target organ conditions, including
diabetic kidney disease. High blood glucose can lead to damage of renal capillaries
causing hyperfiltration by the glomerulus and subsequent microalbuminuria (Kanwar et
al., 2008). Hence, the National Kidney Foundation has recommended intensive glycemic
control in CKD patients by suggesting a target HbA1c of 7% to reduce albuminuria
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progression (KDOQI, 2007). Any further reduction in the target levels of HbA1c should
be avoided due to significantly heightened risks for severe hypoglycemia and all-cause
mortality (Ismail-Beigi et al., 2010; Shurraw et al., 2011).
In an effort to manage their blood glucose levels, diabetic patients are often
prescribed oral antihyperglycemic agents with or without insulin. Unfortunately,
difficulty in maintaining appropriate glycemic control in CKD patients arises as a result
of dosing adjustments required for many medications. For instance, metformin is a firstline medication for the treatment of type 2 diabetes. The use of metformin in patients
with CKD stage 3 or higher is often avoided due to a heightened risk for adverse drug
effects, including lactic acidosis (Lalau et al., 2015). Further complicating glycemic
management is the development of insulin resistance, and hindered insulin secretion and
clearance in CKD patients (Williams and Garg, 2014). Devising appropriate strategies to
optimize the management of hyperglycemia slows the progression of CKD, decreases
cardiovascular risk, and improves overall patient prognosis (The Diabetes Control Group,
1993; The Diabetes Control Group, 1995; Ray et al., 2009).

1.3.2

Cardiovascular Disease in CKD
Hypertension is the most common comorbidity experienced by CKD patients with

a prevalence estimate of up to 75% for those with eGFR less than 60 mL/min/1.73m2
(stages 3-5) (National Kidney Foundation, 2002). Not surprisingly, renal vascular disease
is a main cause for many of the adverse outcomes observed in CKD, including renal
failure, early development and augmented progression of cardiovascular disease, and
premature mortality (Levey et al., 1998). With a growing awareness that renal
impairment patients are more likely to die from an adverse cardiac event than progress to
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ESRD (Keith et al., 2004), all CKD patients are now regarded as the highest risk group
for cardiovascular disease, irrespective of any risk factors (National Kidney Foundation,
2002). The complicated interaction between CKD and cardiovascular disease can be
attributed to the increased risk for both traditional (hypertension, advanced age, diabetes,
and hyperlipidemia) and CKD-specific risk factors (inflammation, malnutrition, mineral
disorders, and anemia). The aggregate of all such risk factors has resulted in a nearly 70%
prevalence estimate of cardiovascular disease among elderly CKD patients—two-fold
greater than what is observed in the general elderly population (Saran et al., 2016).
Congestive heart failure and atherosclerotic heart disease are the two primary
clinical presentations of cardiovascular comorbidity in the CKD population (Saran et al.,
2016). Acceleration in atherosclerotic plaque development has been an evident problem
for hemodialysis patients for over 30 years (Lindner et al., 1974). The asymptomatic
nature of coronary artery disease combined with increased inflammation and oxidative
stress in CKD has created a challenging circumstance for preventing atherosclerosis
progression (deFilippi et al., 2003; Ohtake et al., 2005). Correspondingly, recognition
that vascular calcification is very common amongst CKD patients supports the finding of
a heightened risk for heart failure in this population (Chertow et al., 2002; Moe et al.,
2002). In a large population-based study conducted in the USA, the rate of cardiac failure
in stage 3-5 CKD patients was 3-fold higher as compared with non-CKD subjects
(Kottgen et al., 2007). ESRD patients diagnosed with heart failure at the start of their
renal replacement therapy (RRT) are strongly associated with short and long-term
mortality. Specifically, the median survival time of dialysis patients diagnosed with
baseline heart failure is 36 months, whereas dialysis patients without heart failure has an
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estimated survival of 62 months (Harnett et al., 1995). Although significant
improvements have been made for the management of cardiovascular disease in the
general population, many of the interventions either lack clinical investigation in patients
receiving RRT or have been shown to be less effective. For instance, the lipid-lowering
class of medications known as statins are the best-selling drugs in history due to their
proven efficacy to reduce cardiovascular disease and mortality (Scandinavian Simvastatin
Survival Study Group, 1994; Nawrocki et al., 1995; World Health Organization, 2004;
Epidemiological Studies Unit, 2005). However, three large randomized, placebocontrolled trials studying the use of statins in dialysis patients did not display any survival
benefit (Fellström et al., 2009). These findings have ultimately warranted updates to
clinical practice guidelines recommending statin therapy should no longer be initiated for
dialysis-dependent CKD (Wanner et al., 2005; Baigent et al., 2011; Tonelli et al., 2014).
More prospective trials are required to compare and determine which medications
provide the best cardiovascular protection in subjects treated with RRT.

1.4 Renal Replacement Therapy for End-Stage Renal
Disease
As kidney function and eGFR continue to decline for CKD patients, those who
reach stage 5 will require RRT to prolong survival. A recent report drawing on data from
the Canadian Organ Replacement Register (CORR) has shown that the prevalence of
ESRD patients being treated with some form of RRT has increased over two and half fold
from 13,230 patients in 1995 to 35,281 in 2014 (Canadian Institute for Health
Information, 2016). Clinical decisions for the modality and time of RRT initiation still
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remain controversial. Treatment regimen can be divided into patients of “early-start” or
“late-start” dialysis (Cooper et al., 2010). In early-start, patients are educated and
prepared for RRT during stage 4 CKD to ensure immediate commencement of dialysis
once stage 5 CKD is reached. In comparison, late-start dialysis is initiated when patient
eGFR falls below 15 mL/min/m2 and begin to experience signs and symptoms of uremia
including cognitive decline, fluid overload, electrolyte imbalances, and hormonal
disturbances (Depner, 2001). Results from the IDEAL (Initiating Dialysis Early And
Late) study—a randomized, controlled trial comparing time of dialysis initiation—has
since prompted the National Kidney Foundation to update their guidelines in favour of
commencing dialysis once uremic symptoms become apparent (National Kidney
Foundation, 2015). However, healthcare professionals and patients must still work
together to select an extracorporeal (hemodialysis) or paracorporeal (peritoneal dialysis)
method of dialysis, and whether it will be administered continuously or intermittently.

1.4.1

Hemodialysis
Intermittent, institutional hemodialysis is the most frequently elected form of

RRT and has consistently represented 77% of all new dialysis patients in Canada over the
past decade (Canadian Institute for Health Information, 2016). This mode of RRT is
usually administered thrice weekly for 3-4 hours per session. A vascular access location
must first be surgically created to allow withdrawal of arterial blood from patients into
the hemodialysis machine. Regarding the choice of vascular access, 80% of patients
utilize a central catheter despite numerous functional advantages of fistulas (Moist et al.,
2014). Specifically, fistulas have lower rates of thrombosis and infections, require fewer
interventions, and provide greater longevity in vascular access (Nassar and Ayus, 2001;
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Huber et al., 2003; Perera et al., 2004). Most importantly, patients receiving catheters had
a nearly two and half fold greater risk for mortality as compared to patients dialyzed with
fistulae (Dhingra et al., 2001).
Within the dialyzer, a countercurrent flow of dialysate maintains a concentration
gradient across the dialysis membrane and ensures the diffusion of ions, solutes, and
excess water out of blood. Fluid removal known as ultrafiltration can also be achieved by
varying the hydrostatic pressure of the dialysate to produce a pressure gradient. The
filtered blood can then re-enter systemic circulation of patients through the dialysis
venous line. Dialysate is a salt solution containing glucose and many different ions. The
composition of dialysate is essential for ensuring patients receive effective hemodialysis
therapy since it dictates the balance of electrolyte and mineral concentrations in blood.
For instance, adequate sodium and water removal during dialysis is crucial in minimizing
inter- and intra-dialytic hypertension and edema (Locatelli et al., 2015). Potassium
homeostasis is critical for preventing cardiac arrhythmias, and bicarbonate levels stabilize
physiological pH in order for optimal protein function.
The physiological goals for hemodialysis can differ between patients and require
individualized treatment regimens. Specifically, extracorporeal filtration is dependent on
the blood and dialysate flow rate, duration and frequency of dialysis, and the composition
of dialysis membrane including pore size, surface area and material (National Kidney
Foundation, 2015). Older, conventional dialysis is characterized by low-flux membranes
containing small pore sizes. Recently, there has been a widespread trend in opting for use
of high-flux dialyzers due to their advantage of removing larger solutes and shorter
requirements for dialysis duration (Schneider and Streicher, 1985). Whether high-flux
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dialyzers actually improve patient outcomes still remain controversial. Three large-scale
randomized, controlled trials demonstrated no difference in mortality between low- and
high-flux dialyzers (Eknoyan et al., 2002; Locatelli et al., 2009; Asci et al., 2013).
However, the National Kidney Foundation still recommends high-flux dialyzers be
preferentially used due to improvements in secondary outcomes including cardiac
mortality and hospitalizations (National Kidney Foundation, 2015).

1.4.2

Peritoneal Dialysis
In Canada, peritoneal dialysis accounts for 20% of new ESRD patients requiring

RRT (Canadian Institute for Health Information, 2016). Being able to receive peritoneal
dialysis treatment while at home provides a lifestyle convenience for many of these
patients. The two main approaches for peritoneal dialysis treatment is through automated
peritoneal dialysis (APD) or continuous ambulatory peritoneal dialysis (CAPD)
(Fleming, 2011). Both methods of dialysis involve surgical implantation of a catheter into
the peritoneal cavity to introduce and remove dialysate. APD is characterized by 3 to 6
cycles of dialysate exchange overnight accomplished by a machine, followed by a small
residual volume of dialysate during the day. Conversely, CAPD involves multiple manual
exchanges of 2–3 litres of dialysate during the day, followed by a longer dwell time
overnight (Fleming, 2011). The dialysate composition for either method of peritoneal
dialysis requires a hyperosmotic solution to ensure adequate ion, solute, toxin, and water
removal from the blood, across the peritoneum and into the dialysate. Many of the
complications experienced by patients are due to excessive loss of fluid resulting in
hypovolemic shock or hypotension, and increased infection rates as a consequence of the
permanent catheter (Mehrotra et al., 2016).
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Despite early reports from selected nephrologists suggesting that peritoneal
dialysis is a “second-class therapy for second-class patients by second-class doctors”
(Shaldon et al., 1985), considerable advancements in its application have resulted in
survival benefits comparable to that of institutional hemodialysis (Yeates et al., 2012;
Heaf and Wehberg, 2014; Marshall et al., 2015; van de Luijtgaarden et al., 2016). The
implications of these findings not only allow patients to choose a modality of RRT that
may be better suited for their lifestyle, but it also provides a more economically feasible
method of dialysis to benefit the healthcare system (Karopadi et al., 2013).

1.4.3

Kidney Transplant
The ultimate goal for any dialysis treatment is to prolong patient survival until an

adequate kidney transplant can be received. However, the scarce availability of organs for
transplant restricts millions of people worldwide to long-term RRT (Fleming, 2011). In
Canada, the number of patients waiting for a kidney transplant is steadily increasing
every year but only 40% of those on the waitlist actually receive a kidney (Canadian
Institute for Health Information, 2016). Despite more than 35,000 Canadians being
treated for ESRD, the median wait time for dialysis patients to receive a kidney is 4
years. Fortunately, living organ donation has greatly improved the outlook for renal
transplantation over the past decade and often leads to a healthier, longer-lasting kidney
(Davis and Delmonico, 2005).
To date, a successful kidney allograft is the only treatment for improving GFR
and reversing CKD. Transplant recipients no longer require dialysis therapy once their
kidney begins to function. The risk for heart disease becomes dramatically attenuated,
and erythropoietin synthesis commences within a matter of days allowing patients to
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reach target levels of hemoglobin in 3 months post-surgery (Joist et al., 2006; Zolty et al.,
2008). Accordingly, the quality of life, survival, and long-term prognosis observed in
transplant recipients are far better than ESRD patients requiring dialysis (Purnell et al.,
2013).

1.5 Pharmacokinetic Studies in CKD Patients
Emerging evidence demonstrate alterations of drug absorption, distribution, and
non-renal elimination in renal insufficiency, providing insight as to why CKD patient
responses to pharmacotherapy are still widely variable with frequent adverse drug events
(Bates et al., 1999; Manley et al., 2005; Naud et al., 2012). Urea retention and its
subsequent hydrolysis into ammonia by bacterial urease can increase intestinal pH,
leading to changes in absorption of weakly basic drugs (Pappenheimer and Reiss, 1987;
Velenosi and Urquhart, 2014). Upon reaching systemic circulation, attenuated production
of albumin coinciding with competitive binding by uremic toxins result in elevated free
fraction of medications—the outset for drug toxicity (Sakai et al., 2001). Recent
preclinical and human studies display reductions in non-renal clearance for CKD, which
can ultimately potentiate drug toxicity by prolonging elevated drug concentrations in
plasma (Ahmed et al., 1991; Leblond et al., 2001; De Martin et al., 2006; Michaud et al.,
2006; Naud et al., 2008; Nolin et al., 2009; Velenosi et al., 2012; Velenosi et al., 2014;
Thomson et al., 2015). One possible explanation for this change in drug
pharmacokinetics is the accumulation and circulation of uremic toxins as a result of
reduced clearance in CKD. It has been proposed that indoxyl sulfate and other uremic
toxins can inhibit the function and expression of hepatic drug metabolizing enzymes and
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drug transporters—both being essential contributors to drug disposition (Sun et al., 2004;
Tsujimoto et al., 2010; Fujita et al., 2014).
Realizing that renal impairment can substantially impact all aspects of drug
pharmacokinetics, the FDA Clinical Pharmacology Advisory Committee proposed
several important changes to their 1998 FDA Renal Guidance document (Huang et al.,
2009). The result of this proposal is an updated draft guidance entitled: Guidance for
Industry: Pharmacokinetics in Patients with Impaired Renal Function—Study Design,
Data Analysis, and Impact on Dosing and Labeling. This draft has developed a detailed
algorithm for deciding whether to incorporate patients with renal insufficiency in
pharmacokinetic studies of new chemical entities (NCEs) (Huang et al., 2009). In short,
if NCEs undergo substantial renal elimination (i.e. if at least 30% of the dose is excreted
unchanged in urine), subjects from each stage of CKD must be included in a “full”
pharmacokinetic study. For drugs that are primarily non-renally excreted, the new draft
guidance recommends implementing a “reduced” study design—an important departure
from the 1998 Renal Guidance. This design involves the comparison of drug disposition
in healthy versus ESRD patients who have not yet been prescribed RRT. If drug exposure
is substantially elevated in ESRD patients (e.g. an increase in the AUC of at least 50%, or
a smaller increase for drugs with a narrow therapeutic window), a full renal study must be
conducted.
The importance of implementing a reduced design for drugs that may not exhibit
renal elimination is evident for the analgesic compound, celecoxib—a selective
cyclocooxygenase-2 (COX-2) inhibitor (Swan et al., 2000). It is well-recognized that
prescription of conventional non-steroidal anti-inflammatory drugs (NSAIDs) are
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accompanied by heightened risks for nephrotoxicity, especially for patients with severe
renal insufficiency. However, celecoxib did not undergo any form of renal impairment
study during its drug approval process as its development occurred prior to publication of
the 1998 Renal Guidance, and its primary route of elimination is through hepatic
metabolism. Since then, post-marketing population studies combined with data from
FDA’s Adverse Event Reporting System has demonstrated associations of celecoxib with
acute renal failure (Zhao et al., 2001; Ahmad et al., 2002; Schneider et al., 2006). If
overlooked by physicians, lack of appropriate dosage adjustments for CKD patients can
lead to an accelerated progression into kidney failure (Perazella and Eras, 2000).

1.6 Drug Dialyzability
1.6.1

Current State of Knowledge
Drug dialyzability is defined as the efficiency of drug removal by dialysis. The

‘Dialysis of Drugs,’ an annual publication by the renal pharmacy consultants, has become
a common source of information regarding the dialytic clearance of drugs (Baillie and
Mason, 2013). This excellent resource shows that only 10% of surveyed drugs have
definitive dialyzability information for modern, high-flux hemodialysis (Velenosi and
Urquhart, 2014). An additional 39% of drugs are classified as likely or unlikely dialyzed
based solely on their physicochemical properties with no experimental data, whereas the
remaining 50% of drugs have no available data. As a result, our current understanding of
drug dialyzability is poor. Information regarding dialyzability currently falls into the
following five categories: (1) nonexistent; (2) unsupported statements in product monographs; (3) speculation based on a drug’s physicochemical characteristics; (4)
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pharmacokinetic studies conducted before the modern era of hemodialysis; and (5)
modern pharmacokinetic studies. Case reports of apparently successful dialysis in
overdose settings provide some data, but the applicability of these reports to steady-state
drug dosing is unknown. Overall, the dialyzability of cardiovascular drugs requires
further research to better understand their inherent dialyzability, the clinical ramifications
of dialyzability, and steps that can be taken to better the dosage of these important drugs
in patients receiving hemodialysis.

1.6.2

Drug Factors
Removal of a drug from the body during hemodialysis depends on how readily

the drug crosses the dialyzer and the amount of drug that is accessible in the blood over
the course of a typical hemodialysis session. Diffusion across the dialysis membrane is
limited primarily by a drug’s molecular size, for which molecular weight is a reasonable
proxy. While the upper limit for modern high-permeability dialyzers is approximately
12,000 Da, clearance rates decrease logarithmically with increasing size (Cheung and
Leypoldt, 1997). Regardless of the physical size of the molecule, this characteristic is
meaningful only for the unbound fraction of drug. Binding to serum albumin or
erythrocytes increases a drug’s effective molecular weight far beyond the threshold of
dialyzability. Therefore, the degree of protein binding can greatly reduce a drug’s
dialyzability; however, protein binding is not a fixed characteristic and the dynamic
equilibrium between bound and unbound drug is influenced by factors such as uremia,
pH, and clinical circumstances, including whether patients are in a steady state on
therapeutic dosing or have overdosed (Vanholder et al., 1988; Sue and Shannon, 1992;
Kochansky et al., 2008). A drug’s volume of distribution also affects its dialyzability.
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This parameter is determined by a drug’s lipid solubility and protein binding, and
describes the extent to which a drug is distributed throughout the body compartments.
Hemodialysis readily accesses contents of the extracellular fluid, particularly the blood
compartment. Drugs with low volumes of distribution are largely found in these
compartments and are more readily dialyzed than drugs whose large volumes of
distribution indicate significant distribution to other tissues.

1.6.3

Dialyzer and Dialysis Prescription Factors
Understanding the role played by dialyzer characteristics and the prescription is

important when trying to extrapolate the findings of older dialyzability studies to modern
practice. The clearance rates of small-sized and medium-sized molecules are affected by
a number of parameters that have changed with the advancement of hemodialysis. Small
molecule clearance is largely determined by dialyzer surface area, which is generally
larger in modern dialyzers (Daugirdas et al., 2012). Clearance of medium-sized
molecules is determined more by dialyzer pore size, which has also increased over time
with the introduction of synthetic membrane materials. This also provides higher
ultrafiltration coefficients, resulting in better convective clearance (Bouré and Vanholder,
2004). Newer dialysis prescriptions, such as quotidian dialysis protocols and
hemodiafiltration, are moving modern hemodialysis practice even further away from the
settings in which many drug dialyzabilities were originally determined.

1.6.4

Determining Dialytic Clearance
Further complicating drug dialyzability research is the method selected by

investigators to determine dialytic clearance rates. The two main approaches are the
arterial–venous (A-V) difference method and recovery clearance method (Lee et al.,
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1980; Uehlinger et al., 1996; Tieu et al., 2016). The majority of studies have applied the
A-V difference method to determine dialyzability. This approach is limited by its
inability to account for differences in drug distribution between plasma and red blood
cells, as drug levels are generally measured only within the plasma compartment. The
recovery clearance method is widely accepted as the superior approach to evaluate
dialytic clearance because of its capacity to account for intradialytic hypotension,
variations in dialysis membranes, and changes in nonrenal clearance during dialysis
(Velenosi and Urquhart, 2014). However, many experimental designs lack analytical
techniques sensitive enough to measure highly diluted drugs in total spent dialysate
(around 120 L). Nonetheless, the recovery clearance method is accepted as superior to the
A-V method and studies evaluating dialytic clearance should employ the recovery
clearance method when possible to accurately characterize drug clearance by dialysis.

1.7 Clearance of Cardiovascular Medications During
Hemodialysis
1.7.1

Beta-Adrenergic Receptor Blockers
Epinephrine and norepinephrine are endogenous catecholamines that bind and

activate adrenergic receptors to mediate different physiological responses. These
receptors can be subdivided into alpha and beta receptors (Kidney Disease Outcomes
Quality Initiative, 2004). Focusing on the beta subtype, beta-1 adrenoreceptors are
primarily expressed in heart muscle and their activation generates an increase in
atrioventricular nodal conduction, heart contractility, and heart rate. Localized in the
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bronchial and peripheral vascular smooth muscle, activation of beta-2 adrenoreceptors
causes dilation of vessels and bronchioles.
Beta-adrenergic receptor antagonists (beta blockers) are an important class of
medication for the management of hypertension and cardiovascular disease in patients
receiving hemodialysis. The various classes of beta blockers differ in clinical benefit and
adverse events, mainly due to their selectivity when binding endogenous receptors
(Kidney Disease Outcomes Quality Initiative, 2004). Specifically, selective beta blockers
are agents that preferentially antagonize beta-1 receptors (e.g. atenolol, bisoprolol and
metoprolol) in order to improve cardiac function. Non-selective beta blockers are those
that bind both beta-1 and beta-2 adrenoreceptors, which can lead to additional adverse
events including bronchoconstriction and peripheral vascular symptoms. Carvedilol is a
non-selective beta blocker that also antagonizes alpha receptors.

Left ventricular

hypertrophy (Mark et al., 2006) and sudden cardiac death (McCullough, 2004) are
common manifestations of heart disease in dialysis patients and the use of beta blockers
has been associated with reductions in both the degree of hypertrophy and the risk of
death in this patient population (Cice et al., 2003; Abbott et al., 2004; Hampl et al., 2005;
Nakao et al., 2009; Matsue et al., 2013). With respect to dialyzability, the clearance of
beta blockers during dialysis varies considerably, but the quality of evidence is low
(Table 1.2) (Flouvat et al., 1980; Roux et al., 1980; Miki et al., 1991; Kanegae et al.,
1999). Minimally dialyzable beta blockers include carvedilol, which is 90% proteinbound and difficult to detect in spent dialysate (Miki et al., 1991), and propranolol, which
is also highly protein-bound. Bisoprolol is also likely to be of low dialyzability as
outlined by previous review articles and industry sources (Table 1.3). At the more
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Table 1.2. Dialyzability of beta blockers.
Dialyzability Data
Beta
Blocker

Acebutolol

Atenolol

Bisoprolol

Molecular
Weight
(Daltons)

336

266

325

Protein
binding
(%)

26

10

30

Volume of
distribution
(L/kg)

Specified Dialyzability
Testing Conditions*

Clearance
during
hemodialysis
(ml/min)

Reference

1.2

Recovery method
Single dose
Dialyzer: cuprophane
QD: 700 ml/min
QB: 238 ml/min

42.6

Roux
1980(55)

4.2

A-V Difference method
Single dose
Dialyzer: cuprophane
QD: 700 ml/min
QB: 236 ml/min

42.6

Flouvat
1980(56)

3

A-V Difference method
Single dose
Dialyzer: polysulfone
Q D: ?
QB: ?

50.8

Kanegae
1999(57)

“Not
dialyzable”

Miki
1991(30)

Carvedilol

406

98

1.6

A-V Difference method
Single dose
Dialyzer: ?
Q D: ?
QB: ?

Metoprolol

267

10

3.2

No data

No data

-

Nebivolol

405

98

?

No data

No data

-

* Clearance of a drug during hemodialysis can be determined by the Recovery Method, in which drug
removal is determined from the total spent dialysate, or by the A-V Difference Method, in which clearance
is calculated with the Fick Equation using the difference in drug concentrations between the arterial (A) and
venous (V) limbs of the dialysis machine and the blood flow rate.
Abbreviations: QD, dialysate flow rate; QB, blood flow rate.

23

dialyzable end of the spectrum are a number of beta blockers with minimal protein
binding, including acebutolol, atenolol, and metoprolol. A recently published
retrospective cohort study compared the 90-day risk of mortality among patients on
hemodialysis, who initiated a high versus low dialyzability beta blocker (Weir et al.,
2015). This study demonstrated an increase in the risk of mortality among patients
initiating one of the highly dialyzable agents (metoprolol, atenolol, or acebutolol)
compared to those who started a low dialyzability agent (bisoprolol or propranolol).
These findings suggest that dialyzability of beta blockers may be an important
determinant of drug effectiveness in people receiving hemodialysis. Although this is
thought provoking, shortcomings in the ability to definitively classify dialyzability leaves
the door open for debate and is the primary rationale for experiments in this thesis.

1.7.2

Angiotensin-Converting Enzyme Inhibitors and Angiotensin
Receptor Blockers
ACE inhibitors are commonly prescribed for hypertension, heart failure, or

myocardial infarction because their use improves survival and prevents major
cardiovascular events. The dialyzability of ACE inhibitors is incompletely characterized,
but from existing data, dialyzability appears to vary significantly within this drug class
(Fruncillo et al., 1987; Kelly et al., 1988; Verpooten et al., 1991; Gehr et al., 1993;
Guerin et al., 1993; Fillastre et al., 1996; Yamada et al., 2003). Fosinopril is minimally
dialyzable with a clearance rate during hemodialysis of only 4 ml/min, whereas enalapril
and perindopril are highly dialyzable with clearance rates in excess of 60 ml/min. Other
ACE inhibitors appear to have moderate levels of dialyzability (Supplementary Table C1,
Appendix C) (Fruncillo et al., 1987; Kelly et al., 1988; Verpooten et al., 1991; Gehr et
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al., 1993; Guerin et al., 1993; Fillastre et al., 1996; Yamada et al., 2003). The data
supporting these categorizations are of reasonable quality with many studies conducted in
the modern era using robust pharmacokinetic measurements. However, a significant
amount of the data in this class was collected using low-efficiency, low-flux dialyzers
and was determined using the inferior arterial-venous (A-V) difference method.
Accordingly, it is difficult to compare dialyzability among drugs within this class because
of the differences in methodology used to determine clearance. A recent study measured
short-term mortality and cardiovascular end-points among patients on hemodialysis, who
initiated ACE inhibitors of differing dialyzability (Weir et al., 2015). There was no
difference in outcomes, which, among other factors, may have been the result of
dialyzability misclassification.
Angiotensin receptor blockers (ARBs) appear to express a more uniform level of
dialyzability than ACE inhibitors (Supplementary Table C2, Appendix C) (Sica et al.,
1997; Pfister et al., 1999; Sica et al., 2000; Stangier et al., 2000; Tanaka et al., 2009). All
commonly prescribed agents show very high levels of protein binding. In
pharmacokinetic studies, ARBs are extremely difficult to detect in dialysate, and
differences in ARB concentrations between blood entering and exiting the dialyzer are
very low. This suggests that ARBs are not dialyzable to any meaningful extent. However,
as is frequently the case, most studies with ARBs were not conducted with modern highflux, high-efficiency dialyzers.

1.7.3

Calcium Channel Blockers
Calcium channel blockers (CCBs) are commonly prescribed antihypertensive

medications. Among patients receiving hemodialysis in the United States, approximately
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50–65% are prescribed a CCB (St Peter et al., 2013; Shireman et al., 2014).
Dihydropyridine CCBs (amlodipine, felodipine, nicardipine, and nifedipine) are much
more commonly prescribed than nondihydropyridine CCBs (diltiazem and verapamil) (St
Peter et al., 2013). Studies regarding the dialyzability of CCBs are few and were largely
conducted prior to the modern era of hemodialysis (Supplementary Table C3, Appendix
C) (Martre et al., 1985; Shah and Winer, 1985; Hanyok et al., 1988; Buur et al., 1991;
Kungys et al., 2003). However, CCBs likely have minimal dialyzability as a result of
high protein binding and large volumes of distribution.

1.7.4

Antiplatelet Agents
Patients receiving hemodialysis have an elevated risk of both thrombotic events

and bleeding abnormalities (Rios et al., 2010). The National Kidney Foundation-Kidney
Disease Outcomes Quality Initiative (NKF-KDOQI) recommends the use of antiplatelet
agents to prevent cardiovascular events in patients with CKD. Although the associated
risk of bleeding is well established, it is out-weighed by reductions in myocardial
infarction rates among high-risk patients receiving hemodialysis (Palmer et al., 2013).
Understanding the pharmacokinetics of antiplatelet drugs during dialysis is critically
important to balance this risk-benefit relationship. However, there is a scarcity of data
characterizing the dialyzability of these drugs. Aspirin has been shown to be moderately
dialyzable with clearance rates ranging from 30 to 86 ml/min (Supplementary Table C4,
Appendix C) (Doolan et al., 1951; Spritz et al., 1959; Kallen et al., 1966; Bern et al.,
1980; Jacobsen et al., 1988). These findings were observed in overdose settings, in which
aspirin’s protein binding was likely to be less than its typical 99%. However, the binding
of aspirin to albumin is relatively weak, and this may have contributed to the moderate
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dialytic clearance observed (Kallen et al., 1966). No data on dialyzability are currently
available for modern antiplatelet agents.

1.7.5

Anticoagulant Agents
Although anticoagulants have a proven benefit in the management of

thromboembolic diseases in the general population, for patients with renal disease, there
is little data available to guide treatment. With respect to dialyzability, anticoagulants
vary considerably. Dabigatran, one of the new oral anticoagulants, is highly dialyzable
with whole blood clearance rates in excess of 150 ml/min (Supplementary Table C5,
Appendix C) (Ifudu and Dulin, 1993; Robson, 2000; Murray et al., 2004; Kalicki et al.,
2007; Wagner et al., 2011; Chang et al., 2013; De Vriese et al., 2015). In contrast, the
other oral anticoagulants, including warfarin, apixaban, and rivaroxaban, are minimally
cleared by hemodialysis. As shown in Supplementary Table C5 (Appendix C), there is a
paucity of dialyzability data for injectable direct thrombin inhibitors, factor Xa inhibitors,
and low-molecular-weight heparins. Although argatroban exhibited a 20% increase in
clearance during hemodialysis, this difference was deemed to be clinically insignificant
(Murray et al., 2004). Fondaparinux, a selective inhibitor of factor Xa, had a minimal
dialytic clearance rate of 9.8 ml/min estimated from changes in anti-Xa activity (Kalicki
et al., 2007). The lack of available information on anticoagulant removal by hemodialysis
implicates a need to conduct further studies using high-efficiency, high-flux dialyzers.

1.7.6

Cholesterol-Lowering Agents
Over the past decade, there has been considerable controversy surrounding the

value of cholesterol-lowering medications in patients receiving hemodialysis. Statin or
statin and ezetimibe combination therapy is recommended for nondialysis-dependent
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CKD patients, while dialysis patients should use these medications only if they were
receiving them prior to dialysis initiation (Tonelli et al., 2014). As a class, the
dialyzability of statins seems to be consistently minimal, which is reflective of their high
protein binding and volumes of distribution. Accordingly, Launay-Vacher et al. (2005)
has suggested that most statins can be administered at usual dosages any time before or
after dialysis sessions. However, rosuvastatin had a dialytic clearance rate of 42 ml/min
and pravastatin and its metabolites had higher and more variable rates of clearance,
ranging from 38 to 81 ml/min, depending on the method used to determine dialyzability
(Supplementary Table C6, Appendix C) (Gehr et al., 1997; Appel-Dingemanse et al.,
2002; Lins et al., 2003; Ichimaru et al., 2004; Birmingham et al., 2013). Ezetimibe has no
available data but should be a focus of future research given its increasing use (Lu et al.,
2014), and the trend toward benefit among patients on dialysis observed in the SHARP
trial (Baigent et al., 2011).

1.8 Objectives and Hypothesis
1.8.1

Rationale
Of all comorbidities, cardiovascular disease has the greatest negative impact in

CKD accounting for nearly 45% of mortalities in hemodialysis patients—an incidence
10-20 times greater than the general population (Foley et al., 1998; Cheung et al., 2004;
Collins et al., 2010). Over the past four decades, there have been vast advancements for
the treatment of cardiovascular disease due in part to the emergence of beta blockers.
This class of medication promotes cardiovascular improvements by decreasing blood
pressure, heart rate, myocardial oxygen demand, arrhythmia, oxidative stress, and
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improving left ventricular function (Lopez-Sendon et al., 2004). More importantly, the
administration of beta blockers to reduce mortality in cardiovascular disease patients has
been observed in numerous prospective randomized clinical trials (Hansson et al., 1999;
Cice et al., 2003). It is based on the strength of these findings that beta blockers are
administered to 64% of dialysis patients exhibiting cardiovascular complications, and
have become a cornerstone treatment in CKD (Frankenfield et al., 2012).
Many studies indicate altered medication pharmacokinetics in CKD, including
both renal and non-renal drug elimination (Leblond et al., 2000; Nolin et al., 2009;
Velenosi et al., 2012). Accordingly, expectations that beta blockers will deliver similar
therapeutic efficacy in hemodialysis patients as compared with the general population is
based on very little evidence. Most pharmacologic interventions have not included
dialysis patients in their drug development process resulting in a lack of appropriate
prescription recommendations (Ishani et al., 2004; Zhang et al., 2009; Frankenfield et al.,
2012; Matzke et al., 2015). In particular, drug dialyzability is likely to vary amongst
different beta blockers and should be considered when they are administered to
hemodialysis patients. For instance, the use of drugs that are highly dialyzable can result
in sub-therapeutic plasma concentration during hemodialysis and lead to an increased risk
for adverse clinical outcomes (Figure 1.1). The unfortunate circumstance is that there is a
paucity of available data to describe the dialyzability of beta blockers and many other
currently marketed medications. Of the available information, most were obtained prior
to implementation of high-flux, high-efficiency dialysis machines rendering many of the
older studies irrelevant. The interdisciplinary approach to bridge pharmacology with
clinical epidemiology uniquely positions us to determine conclusively the dialyzability of
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beta blockers and its impact on cardiovascular outcomes. Data generated by this project
are expected to be translated to future clinical practice guidelines, potentially optimizing
pharmacotherapy and improving quality of life for chronic hemodialysis patients.
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Figure 1.1. Potential effects of dialyzability on plasma drug concentration.
We expect that the dialyzability between medications of the same drug class will differ
substantially based on their physicochemical properties. Drugs that are highly dialyzed
(○) will result in sub-therapeutic concentrations preventing their ability to mediate their
intended pharmacological effect. Conversely, drugs that are minimally dialyzed (□) will
remain within their therapeutic window due to lack of clearance during hemodialysis.
Consideration to preferentially administer poorly dialyzed drugs to hemodialysis patients
should be considered.
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1.8.2

Hypothesis

My governing hypothesis is that atenolol and metoprolol will be classified as “high
dialyzability” beta blockers, while bisoprolol and carvedilol will be classified as “low
dialyzability” beta blockers.

1.8.3

Specific Objective

Determine the pharmacokinetics and degree of dialyzability for the four most
commonly prescribed beta blockers: atenolol, bisoprolol, carvedilol and metoprolol.
Prior to investigating the effect of beta blocker dialyzability on clinical outcomes,
the dialytic clearance rates were calculated and compared for definitive characterization
of drug dialyzability. This was accomplished by conducting a pharmacokinetic, 4-way
crossover study with ESRD patients receiving modern, high-flux hemodialysis. Ultraperformance liquid chromatography coupled to mass spectrometry was used to measure
plasma drug concentrations.
Hypotheses on which beta blockers would be extensively or poorly dialyzed was
determined after reviewing physicochemical properties of the drugs, consulting industry
sources, and evaluating review articles. Statements regarding the dialyzability of each
beta blocker are summarized in Table 1.3. In summary, we expected to find that atenolol
and metoprolol will be extensively cleared by hemodialysis, while bisoprolol and
metoprolol will be poorly dialyzed.
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Table 1.3. Physicochemical properties and dialyzability statements for study beta blockers.
Industry Statements
Beta
Blocker

Review Articles
Expected
Dialyzability

Product
Monographs

Dialysis of Drugs
2013a

Levin et
al. 2010

Chazon
and Jean
2006

Chen et
al.2006

Redon et
al. 2010

Atenolol

Molecular Weight: 266 Daltons
Water Solubility: 13,500 mg/L
Protein Binding: 10%
VD: 4.2 L/kg

Moderately
Dialyzable
(20–50 %)

Conventional HD: Yes
Modern HD: Likely

D

D

D

D

High
Dialyzability

Bisoprolol

Molecular Weight: 325 Daltons
Water Solubility: 2,240 mg/L
Protein Binding: 30%
VD: 3.0 L/kg

Not
Dialyzable

Conventional HD: Yes
Modern HD: No Data

ND

ND

ND

ND

Low
Dialyzability

Carvedilol

Molecular Weight: 406 Daltons
Water Solubility: 0.583 mg/L
Protein Binding: >98%
VD: 1.6 L/kg

Not
Dialyzable

Conventional HD: No
Modern HD: Unlikely

ND

ND

ND

ND

Low
Dialyzability

Metoprolol

Molecular Weight: 267 Daltons
Water Solubility: 16,900 mg/L
Protein Binding: 10%
VD: 3.2 L/kg

No
Statement

Conventional HD: Yes
Modern HD: Likely

D

D

D

ND

High
Dialyzability

a

Physicochemical Properties

Annual guidelines published by Renal Pharmacy Consultants, LLC (Saline, Michigan, USA). Dialyzability based on scientific and industry data
VD
Volume of distribution.
HD
Hemodialysis.
Yes
Dialysis was found to enhance drug clearance from previously published studies.
No
Dialysis was not found to enhance drug clearance from previously published studies.
No Data
No data or assumptions from physicochemical properties exist to describe drug dialyzability.
Likely
Drug is likely to be cleared by hemodialysis based on physicochemical parameters, but no data exists.
Unlikely
Drug is unlikely to be cleared by hemodialysis based on physicochemical parameters, but no data exists.
D
Drug is listed as dialyzable in corresponding review article.
ND
Drug is listed as not dialyzable in corresponding review article.
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MATERIALS AND METHODS
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2.1 Characterizing Beta Blocker Dialyzability
2.1.1

Study Design and Participant Eligibility
Eight hemodialysis patients were prospectively recruited from the London Health

Sciences Centre (LHSC) to participate in a clinical pharmacokinetic study on the
dialyzability of commonly used beta blockers. This study was approved by the Health
Sciences Research Ethics Board at Western University (Approval Number 104909). The
sample size was determined based on previously completed dialyzability studies using
older, conventional dialyzers (Flouvat et al., 1980; Campese et al., 1985; Payton et al.,
1987; Buttazzoni et al., 2006; Sowinski et al., 2008). The study was an open-label, 4-way
crossover trial of the four most commonly prescribed beta blockers in Ontario: atenolol
(50 mg), bisoprolol (5 mg), carvedilol (6.25 mg), and metoprolol (50 mg). A randomly
selected, single oral dose of one of the four beta blockers was administered to the subjects
4 hours prior to hemodialysis initiation. A washout period of at least 2 days was required
before subjects received the next beta blocker, and this process continued until all 4 beta
blockers were administered to all subjects. Four hours following drug administration,
dialysis was initiated according to the patient’s regular treatment. During dialysis, blood
samples were collected from the arterial and venous ports at 6 different time points for
each patient. For subjects who received dialysis for 4 hours, blood was drawn 0.0, 0.5,
1.0, 2.0, 3.0, and 4.0 hours after dialysis initiation. For subjects treated with dialysis for
3.5 hours, blood samples were collected 0.0, 0.5, 1.0, 1.5, 2.5, and 3.5 hours after starting
dialysis. Lastly, subjects who were prescribed a 3 hour dialysis duration had blood drawn
0.0, 0.5, 1.0, 1.5, 2.5, and 3.0 hours after dialysis initiation. Total spent dialysate was
recovered throughout the entirety of the hemodialysis treatment by diverting the waste
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from the drain to a 200 L, food-grade plastic barrel. All samples were obtained for
measurement of beta blocker concentrations.
Subject eligibility for study enrollment was determined by the following inclusion
criteria: (1) at least 18 years of age, and (2) patients were on standard, thrice weekly
hemodialysis for at least 90 days prior to first study session. Subjects were excluded from
study enrollment if any of the following exclusion criteria was evident: (1) significant
gastrointestinal or liver disease, (2) body mass index greater than 40 kg/m2, (3)
prescription of contraindicated medications (amiodarone, digoxin, phenytoin, quinidine,
and others) or prior adverse drug reactions to beta blockers, and (4) bradycardia (heart
rate less than 50 bpm) or hypotension (systolic blood pressure less than 100 mmHg)
within the last 2 weeks prior to study commencement. Appendix D highlights in greater
detail the specific inclusion and exclusion criteria applied to the subject screening
process. Patients who did meet the eligibility criteria were enrolled on the provision of
informed written consent in accordance with the Declaration of Helsinki.

2.1.2

Clinical Data Collection and Follow-Up
Demographic information was collected at the time of study enrollment. Patient

information on their current medications, health status, and hemodialysis treatment plan
was obtained by interview and review of medical records. Blood samples from the
arterial port before and after the hemodialysis session were obtained for hematocrit
assessment conducted by the London Laboratory Services Group using standard methods
(London, ON.). Subjects were monitored for adverse events throughout their dialysis
session, and adjustments to hemodialysis were made by healthcare professionals
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according to standard hemodialysis protocol. The study period was from February 2015
to March 2016.

2.1.3

Chemical Reagents and Drugs
Atenolol (50 mg, Teva Pharmaceuticals Ltd.), bisoprolol fumarate (5 mg, Apotex

Inc.), PMS-carvedilol (6.25 mg, Pharmascience Inc.), and metoprolol tartrate (50 mg,
Mylan Pharmaceuticals Inc.) administered to subjects in the study were purchased from
the pharmacy at London Health Sciences Centre (LHSC, London, ON). Atenolol,
bisoprolol

hemifumarate,

carvedilol,

metoprolol,

atenolol-d7,

bisoprolol-d7

hemifumarate, carvedilol-d3, and metoprolol-d7 standards used for drug level analysis
were purchased from Toronto Research Chemicals (Toronto, ON).

2.1.4

Beta Blocker Extraction and Liquid Chromatography
Blood samples were centrifuged at 2000g for 10 minutes within one hour of

collection. Plasma was separated from blood cells and subsequently stored with dialysate
samples at -80°C until analysis. Plasma and dialysate concentrations of atenolol,
bisoprolol, carvedilol, and metoprolol were determined using solid phase extraction
(SPE) followed by ultra-performance liquid chromatography coupled with quadrupole
time-of-flight mass spectrometry (UPLC-QToFMS). Beta blocker extraction from plasma
and dialysate samples were conducted with SPE cartridges (C18, Strata-X Polymeric
Reversed Phase 33 µm) obtained from Phenomenex (Torrance, CA) and conditioned
according to manufacturer’s specifications. Atenolol-d7, bisoprolol-d7, carvedilol-d3,
and metoprolol-d7, all at 50 ng/mL, were used as internal standards for drug
quantification. Plasma, dialysate, and internal standards were passed across the SPE
cartridges under a vacuum pressure of less than 250 mmHg. Cartridges were washed with
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1 mL of nano-pure water followed by 1 mL of 20% methanol in water, and analytes were
eluted into clean glass test tubes with 1 ml of methanol solution containing 0.1%
trifluoroacetic acid. Eluents were dried in a 40°C water bath using an Organomation NEVAPTM nitrogen evaporator (Berlin, MA) which was followed by sample reconstitution
in mobile phase. Dried eluents that contained carvedilol from plasma extractions were
concentrated 10-fold to ensure adequate compound detection, while samples containing
other beta blockers were not concentrated before analysis. Dried eluents from dialysate
extractions were concentrated 100-fold to ensure adequate beta blocker signal during
analysis. Reconstituted samples were injected at a volume of 5 µL with a flow rate of 0.7
mL/min on a Phenomenex Kinetex C8 column (1.7 µm particle size, 50 x 2.1 mm) for
analyte separation. The Waters ACQUITY UPLCTM I-Class system (Waters, Milford,
MA) autosampler maintained the column temperature at 40°C. Water (A) and acetonitrile
(B), both containing 0.1% formic acid, were the mobile phase solutions used for
compound elution. The UPLC elution parameters were as follows: 0.00–0.20 min, 2% B;
0.20–1.50 min, 2–80% B; 1.50–2.50 min, 80% B; and 2.51–3.51 min, 2% B.

2.1.5

Beta Blocker Analysis with Mass Spectrometry
Mass spectrometry was conducted using a Waters XevoTM G2S-QTofMS. Beta

blockers were measured using positive electrospray ionization (ESI) mode. The capillary
and cone voltages were set at 0.5 kV and 40 V, respectively and a source temperature of
150°C was maintained. The desolvation gas flow was 1200 L/h at a temperature of
650°C, and the cone gas flow was 50 L/h. The data was acquired in centroid mode using
an MSE method allowing for both MS and MS/MS fragmentation during a single run.
Acquisition samples were measured in positive polarity with extended dynamic range and
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the analyzer mode set to resolution. Both functions 1 (low energy collision) and 2 (high
energy collision) of the centroid method acquired data within a mass range of 50 to 1200
Da and a scan time of 0.05s. Collision energy for function 1 of the MSE method was set
at 0V, while function 2 was ramped from 15–50 V. Function 3 acquired lockspray to
maintain accurate mass detection and reproducibility. The lockmass consisted of leucineenkephalin (1ng/µL) set at a flow rate of 10 µL/min. A lockspray frequency of 10s was
applied and data was averaged over 3 scans. Acquisition of data was controlled by
Waters MassLynx v4.1 software and peak integration of sample chromatograms were
conducted with QuanLynx software (Waters, MA, USA).

2.1.6

Determining Dialytic Clearance
The two main methods to evaluate the clearance of medications during

hemodialysis are the arterial-venous (A-V) difference method (1) and recovery clearance
method (2), which are described by the following equations (Lee et al., 1980; Uehlinger
et al., 1996; Tieu et al., 2016):
(1)

CLA-V = QP [(Aconc – Vconc) / Aconc]
QP = QB (1 – Hct)

Where CLA-V is A-V difference clearance, QP is plasma flow rate, QB is blood
flow rate, Hct is hematocrit, Aconc is arterial plasma drug concentration, and Vconc is
venous plasma drug concentration.
(2) CLR = Rdrug / AUC0-T
Where CLR is dialyzer clearance, Rdrug is total amount of drug recovered in
dialysate calculated by multiplying the dialysate drug concentration by total spent
dialysate volume, and AUC0-T is area under the plasma concentration-time curve during
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dialysis. The AUC0-T was calculated by the trapezoidal method using GraphPad Prism
(version 6.01 for Windows; GraphPad Software, San Diego, CA).

2.1.7

Other Pharmacokinetic Parameters
The following pharmacokinetic parameters were determined by applying different

equations as outlined by Rowland and Tozer (1995): (3) total clearance, (4) non-dialytic
clearance, (5) elimination half-life, (6) fraction of total clearance due to dialysis, (7)
fraction of drug eliminated during dialysis, and (8) post-dialysis supplemental dose.
(3) CLTotal = (CT=0*VD*FU)/ AUC0T
Where CLTotal is the total clearance during the hemodialysis session, CT=0 is the
arterial beta blocker concentration at the beginning of dialysis, VD is the volume of
distribution, FU is the fraction of drug unbound, and AUC0T is the area under the plasma
concentration-time curve during dialysis.
(4) CLNon-dialysis = CLTotal – CLDialysis
Where CLNon-dialysis is drug clearance due to non-dialytic mechanisms, CLTotal is
total drug clearance, and CLDialysis is dialytic clearance
(5) T1/2 = 0.693/kD
Where T1/2 is the elimination half-life of the drug during hemodialysis, and kD is
the elimination rate constant as determined by calculating the slope of the line after
plotting the logarithm of plasma drug levels versus time on hemodialysis.
(6) FDialysis = CLDialysis / CLTotal
Where FDialysis is the fraction of total drug clearance occurring by dialysis
(7) FDrug = FDialysis*(1 – e –KD*T)
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Where FDrug is the fraction of drug initially in the body eliminated during
hemodialysis, kD is the elimination rate constant during hemodialysis, and T is the length
of the hemodialysis session
(8) Supplemental Dose = CT=0*VD*(e–KE*T – e–KD*T)
Where kE is the elimination rate constant of the beta blocker in CKD patients

2.1.8

Statistical Analysis
All statistical analysis was performed using GraphPad Prism (version 6.01 for

Windows; GraphPad Software, San Diego, CA). Statistical differences between atenolol,
bisoprolol, carvedilol and metoprolol treatments were assessed by one-way analysis of
variance (ANOVA) followed by Tukey’s post-hoc test. Results are presented as mean ±
SD and a p-value less than 0.05 was considered statistically significant.
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3

RESULTS
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3.1 Assay Validation and Performance
In order to determine the concentration of beta blockers found in clinical samples,
a UPLC-MS method was developed and validated to quantify atenolol, bisoprolol,
carvedilol and metoprolol in plasma and dialysate. Sample preparation with SPE
cartridges were assessed for beta blocker recovery by comparing the mean concentration
of 5 analytical replicates to the nominal concentration. The percent recovery of atenolol,
bisoprolol, carvedilol, and metoprolol were 101%, 112%, 93%, and 112%, respectively.
In plasma, a calibration curve over the concentration range of 0.488–500.0 ng/ml
was created. Patient plasma concentrations for each beta blocker were within this range
and suitable for sample analysis. Using a signal-to-noise ratio greater than 3:1, the lower
limit of detection (LLOD) for atenolol, bisoprolol, carvedilol, and metoprolol in plasma
was 0.0153, 0.0305, 0.4883 and 0.0305 ng/mL, respectively. In dialysate, a calibration
curve of 0.488–500.0 ng/mL was used for sample analysis. Atenolol, bisoprolol, and
metoprolol levels in total spent dialysate were quantifiable using this range of
concentrations; however, most dialysate samples containing carvedilol were below the
lower limit of quantification (LLOQ) due to minimal clearance by dialysis. As a result,
the intra-day accuracy and precision was assessed using 5 analytical replicates of the
lowest concentration on the dialysate calibration curve. Accuracy, expressed as a bias
percentage, was determined by comparing the mean measured concentration to the
nominal concentration. Precision was determined by calculating the coefficient of
variation (CV) percentage of the 5 analytical replicates. Using a signal-to-noise ratio of at
least 10:1, the LLOQ of the calibration curve displayed acceptable accuracy (< 15%) and
precision (< 10%) for all beta blockers. Specifically, the bias and CV were 4.2% and
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1.1% for atenolol, 2.0% and 2.7% for bisoprolol, -6.0% and 12.5% for carvedilol, and
1.9% and 1.5% for metoprolol. The LLOD for atenolol, bisoprolol, and metoprolol was
0.0076 ng/mL while carvedilol had a LLOD of 0.0305 ng/mL, all of which were
determined using a signal-to-noise ratio of at least 3:1.

3.2 Baseline Characteristics of Subjects
In total, eight ESRD patients requiring chronic hemodialysis were enrolled and
each patient had received hemodialysis treatment for greater than three months. Beta
blocker treatments were well tolerated by all study participants and no serious adverse
drug reactions occurred. No abnormalities in heart rate and blood pressure were observed
during the course of the study. Every subject completed the pharmacokinetic 4-way
crossover trial and all but one of the patients was male (Table 3.1). The mean age of
subjects was 58 years (ranging from 28 to 80 years), mean height was 1.70 m and mean
weight was 95.1 kg. The mean body mass index was 32.6 kg/m2. The primary causes for
CKD diagnosis were diabetes mellitus (n=1), hypertension (n=1), rapidly progressive
glomerulonephritis (n=1), polycystic kidney disease (n=1), reflux nephropathy (n=1), and
a combination of both diabetes and hypertension (n=3). Hemodialysis sessions ranged
from 3 to 4 hours with a treatment interval of 3 times per week. Fractional clearance of
urea (Kt/V), also known as dialysis adequacy, has been shown to have a strong, positive
correlation with patient mortality (Lowrie et al., 1981; Gotch and Sargent, 1985; Shinzato
et al., 1997). The National Kidney Foundation has made recommendations for a
minimum delivered Kt/V value of 1.2–1.4 as higher target levels do not improve survival,
while lower values increase risk for patient morbidity (Lowrie et al., 1981; Shinzato et
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al., 1997; Eknoyan et al., 2002; National Kidney Foundation, 2015). Four of the eight
subjects had Kt/V values below the recommended target (Table 3.1). In regards to
vascular access, 4 patients had a central catheter insertion at the right internal jugular vein
while the other 4 subjects had an arteriovenous fistula in place for blood removal and
return. All but one patient had higher hematocrit levels post-dialysis as compared to their
pre-dialysis state.
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Hematocrit, pre0.27 ± 0.01 0.30 ± 0.01 0.33 ± 0.01 0.29 ± 0.01
0.27 ± 0.01 0.28 ± 0.01 0.29 ± 0.02 0.35 ± 0.01
dialysis*
Hematocrit, post0.24 ± 0.01 0.34 ± 0.02 0.36 ± 0.01 0.33 ± 0.01
0.28 ± 0.01 0.30 ± 0.01 0.32 ± 0.03 0.37 ± 0.01
dialysis*
Abbreviations: RPGN, rapidly progressive glomerulonephritis; DM, diabetes mellitus; HTN, hypertension; PCKD, polycystic kidney
disease. * Mean ± SD
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Body Mass Index
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Caucasian

Male

BB002

Age

Ethnicity

Sex

Subject ID

Table 3.1. Background characteristics of chronic hemodialysis subjects.
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3.3 Dialyzability of Beta Blockers in Chronic Hemodialysis
Patients
The effective blood flow rate and pre-dialysis hematocrit measurements for each
subject is shown in Table 3.1. These two variables were combined with the difference in
beta blocker concentrations in the arterial and venous ports to calculate dialyzability
values using the arterial-venous difference equation (Equation 1). As a result, the dialytic
clearance rates for atenolol, bisoprolol, and metoprolol are (mean ± SD) 162.1 ± 22.2,
88.9 ± 15.7, and 106.6 ± 18.1 mL/min, respectively (Figure 3.1). The rates of removal for
these 3 beta blockers are significantly higher than carvedilol at 17.3 ± 14.8 mL/min (P <
0.01). Additionally, the clearance of atenolol during hemodialysis is considerably
elevated when compared to bisoprolol and metoprolol (P < 0.01), whereas bisoprolol and
metoprolol are not significantly different from each other.
Collection and analysis of plasma samples over the duration of the hemodialysis
session allowed us to create plasma concentration-time profiles (Figure 3.2) and
determine the level of beta blocker exposure for each subject (reported as AUC0T). For
atenolol, bisoprolol, carvedilol and metoprolol, patient drug exposure was 827.9, 180.7,
150.5, and 106.9 ng∙h/mL. The amount of beta blocker measured in total spent dialysate
was 3.67 mg, 0.46 mg, 0.00 mg, and 0.56 mg, respectively. AUC values and the total
amount of drug recovered in dialysate were applied to the recovery clearance method
(Equation 2) to produce comparable dialytic clearance rates between atenolol and
metoprolol at 71.8 ± 20.5 and 86.4 ± 27.8 mL/min, respectively (Figure 3.3). The
clearance for both of these beta blockers during hemodialysis was considerably higher
than bisoprolol at 43.7 ± 8.8 mL/min (P < 0.05 compared to atenolol and P < 0.01
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compared to metoprolol). When compared to the other beta blockers, carvedilol displayed
a substantially lower clearance rate at 0.2 ± 0.6 mL/min (P < 0.01)
Based on data from the recovery clearance method, atenolol and metoprolol can
be classified as beta blockers with “high dialyzability”. Similar findings from both the AV difference and recovery clearance methods classifies bisoprolol as a drug of “moderate
dialyzability”, while carvedilol can be categorized as a “low dialyzability” beta blocker.
These beta blocker classifications were incorporated into the study design for a
provincial-wide, population-based retrospective cohort study.
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Figure 3.1. Clearance rate of beta blockers during hemodialysis calculated using the
arterial-venous difference equation.
Dialytic clearance values for the four beta-blockers (atenolol, bisoprolol, carvedilol, and
metoprolol) during hemodialysis in end-stage renal disease patients. Plasma
concentration of beta blockers were determined using ultra-performance liquid
chromatography coupled to a quadrupole time-of-flight mass spectrometer (UPLCQToFMS) and dialyzability was calculated using the arterial-venous (A-V) difference
method. Results are presented as mean ± SD with n=8 for each treatment group. # P <
0.01 relative to atenolol, and * P < 0.01 for carvedilol relative to all other beta blockers.
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Figure 3.2. Beta blocker plasma concentration-time profiles of end-stage renal
disease patients during hemodialysis.
Plasma concentration-time profiles of atenolol (A), bisoprolol (B), carvedilol (C), and
metoprolol (D) during hemodialysis in end-stage renal disease patients. Each subject
received a single oral dose of a beta-blocker four hours prior to dialysis onset. Plasma
concentration of beta blockers were determined using ultra-performance liquid
chromatography coupled to a quadrupole time-of-flight mass spectrometer (UPLCQToFMS). Results are presented as mean ± SD with n=8 for all treatment groups.
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Figure 3.3. Clearance rate of beta blockers during hemodialysis calculated using the
recovery clearance equation.
Dialytic clearance values for the four beta-blockers (A) atenolol, (B) bisoprolol, (C)
carvedilol, and (D) metoprolol, during hemodialysis in end-stage renal disease patients.
Plasma concentration of beta blockers were determined using ultra-performance liquid
chromatography coupled to a quadrupole time-of-flight mass spectrometer (UPLCQToFMS) and dialyzability was calculated using the recovery clearance method. Results
are presented as mean ± SD with n=8 for each treatment group. * P < 0.01 for carvedilol
relative to all other beta blockers, # P < 0.05 relative to bisoprolol, and ## P < 0.01
relative to bisoprolol.
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3.4 Additional Pharmacokinetic Parameters
Additional pharmacokinetic parameters were investigated for each beta blocker
during hemodialysis (Table 3.3). Literature values for volume of distribution (VD),
fraction of drug unbound (FU) and elimination rate constant (kE) in CKD patients not
being treated with HD were used to determine the total clearance of beta blockers. For
atenolol, the reported value of VD is 0.90 L/kg with an FU of 0.84–0.94 and kE of 0.0225
h-1 (Kirch et al., 1981; AstraZeneca Canada Inc., 2011). The VD, FU and kE of bisoprolol
are 1.84 L/kg, 0.70, and 0.0286 h-1, respectively (Kirch et al., 1987; Payton et al., 1987;
Apotex Inc., 2004). In non-CKD patients, carvedilol has a VD of 1.68 L/kg with less than
2% of the drug bound to plasma proteins (von Mollendorff et al., 1987; Auro Pharma
Inc., 2013). The kE observed in patients with advanced renal insufficiency was 0.104
(Gehr et al., 1999). Lastly, the VD, FU and kE for metoprolol are 3.50 L/kg, 0.90 and
0.139 h-1, respectively (Jordo et al., 1980; Novartis Pharma, 2015).
These variables were used to calculate the total clearance of each beta blocker
during dialysis (Table 3.2). Metoprolol has a total clearance of 2364.4 mL/min, which is
markedly higher when compared to atenolol (524.0 mL/min), bisoprolol (700.3), and
carvedilol (810.8 mL/min, P < 0.01). The proportion of clearance due to dialytic
elimination is 0.14 for atenolol, 0.07 for bisoprolol, 0.00 for carvedilol and 0.04 for
metoprolol. During dialysis, the elimination half-life of atenolol was 3.88 hours
corresponding to a 54% reduction in plasma concentration. Bisoprolol concentration
decreased by 33% over the dialysis session producing a half-life of 7.00 hours, which is
considerably longer when compared to the other beta blockers (P < 0.01). Plasma
concentration of carvedilol decreased by 34%, which corresponds to a half-life of 3.84
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hours. Lastly, the half-life of metoprolol during hemodialysis was 2.85 hours which was
determined from an overall 61% reduction in plasma concentration.
After the hemodialysis session, the mean supplemental dose for bisoprolol as a
percentage of the initial administered dose is 38% (1.9 mg). This is not significantly
different from atenolol at 23% (11.4 mg); however, bisoprolol does require a markedly
higher post-dialysis dose as compared with carvedilol at 14% (0.87 mg) and metoprolol
at 5.5% (2.7 mg, P < 0.05).
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Table 3.2 Pharmacokinetic parameters of beta blocker treatments during hemodialysis.
Hemodialysis time of subjects may vary depending on physician recommendations.
Atenolol
(50mg)

Bisoprolol
(5mg)

Carvedilol
(6.25mg)

Metoprolol
(50mg)

Amount Dialyzed
(% of initial dose)

7.34 ± 2.87 Ω

9.30 ± 4.92Ω

0.00 ± 0.00

1.03 ± 0.68

AUC0T (ng∙h/mL)

827.9 ± 146.5* 180.9 ± 99.31

89.56 ± 77.84

106.9 ± 90.6

Beta Blocker

CLTotal (mL/min)

524.2 ± 93.1

700.3 ± 170.7

810.8 ± 275.3

2364.4 ± 560.0*

CLNon-dialysis
(mL/min)

452.4 ± 93.2

656.6 ± 170.4

810.6 ± 275.4

2278.0 ± 548.7*

T1/2 on
hemodialysis (h)

3.88 ± 0.86

7.01 ± 2.12*

3.84 ± 0.85

2.85 ± 0.81

FDialysis

0.14 ± 0.05*

0.07 ± 0.02

0.00 ± 0.00 §

0.04 ± 0.01

FDrug

0.07 ± 0.02*

0.02 ± 0.01

0.00 ± 0.00 §

0.02 ± 0.01

Supplemental Dose
22.8 ± 5.6
38.0 ± 20.6 Ω
13.9 ± 17.1
5.5 ± 2.9
as % of initial dose
(11.4 ± 2.8)
(1.90 ± 1.03)
(0.87 ± 1.07)
(2.74 ± 1.45)
(dose in mg)
AUC0T is the area under the concentration-time curve during hemodialysis
CLTotal is total clearance of the drug during hemodialysis (dialytic and non-dialytic
components)
CLNon-dialysis is clearance of the drug due to non-dialytic mechanisms
T1/2 on hemodialysis is half-life of the drug during hemodialysis
FDialysis is fraction of clearance due to hemodialysis
FDrug is fraction of drug initially in body eliminated by hemodialysis
Supplemental Dose is the dose of beta blocker required after hemodialysis to reach the
drug level that was observed in the patient prior to dialysis.
Data are presented as mean ± SD with n=8 for each beta blocker group.
Ω P < 0.01 relative to carvedilol and metoprolol
* P < 0.01 relative to all other beta blockers
§ P < 0.01 for carvedilol relative to bisoprolol and metoprolol
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4

DISCUSSION
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4.1

Summary of Results

4.1.1

Clinical Pharmacokinetic Study
In this thesis, we outlined a dialyzability study design and various

pharmacokinetic equations that were applied to a cohort of hemodialysis patients in order
to define clinically-relevant parameters pertaining to dialytic elimination of drugs. With
only 10% of currently marketed medications having definitive dialyzability information
based on experimental data (Velenosi and Urquhart, 2014), this study was conducted with
a primary focus on determining the dialytic clearance of the four most commonly
prescribed beta blockers in Ontario. Additionally, many of the studies that do exist have
become considerably outdated due to the nearly universal switch from “conventional” to
“high-flux” dialysis membranes. This study is the first to assess beta blocker dialyzability
using the recovery clearance method in ESRD patients during modern, high-flux, highefficiency hemodialysis treatment.
As expected, our findings demonstrate that both atenolol and metoprolol are
extensively removed during hemodialysis. Despite renal excretion accounting for only
5% of metoprolol clearance (Regardh and Johnsson, 1980), both atenolol and metoprolol
have physicochemical properties that enable them to be readily dialyzed. For instance,
both drugs are only 10% bound to plasma proteins, are highly water soluble, and have
similarly low molecular weights at 270 Da—well below the upper limit of 12,000 Da for
modern dialyzers (McAinsh, 1977; Regardh and Johnsson, 1980; Cheung and Leypoldt,
1997). Despite metoprolol being the second most frequently used antihypertensive agent
in National Health and Nutrition Examination Survey (NHANES) 2009 to 2010 (Gu et
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al., 2012), no previous studies have been conducted to determine its dialyzability. As for
atenolol, the A-V difference method applied by Flouvat et al. (1980) produced a
clearance rate of 42.6 mL/min for ESRD patients on a coil kidney dialysis with
cuprophane membrane. Using the same equation, the contemporary, high-flux
polysulfone based dialyzers prescribed to subjects in our study generated a substantially
higher dialytic clearance of 162.1 mL/min. When the more reliable recovery clearance
equation was applied, the dialyzability of atenolol at 71.8 mL/min was still higher than
the value determined by Flouvat and colleagues (1980). These findings support the notion
that older dialyzability studies are becoming unreliable in their ability to provide
pharmacokinetic information when treating patients with modern dialyzers.
As for carvedilol, its physicochemical properties are highlighted by a larger
volume of distribution and decreased water solubility, both of which would suggest
minimal or low dialytic clearance (GlaxoSmithKline Inc.). However, the primary factor
causing its negligible dialytic clearance is its extensive protein binding at 98% (Varin et
al., 1986). This conclusion was also drawn by Miki et al. (1991) after finding a nonsignificant difference in carvedilol levels between the arterial and venous ports of dialysis
patients. Although carvedilol displayed a small but measurable value of dialytic clearance
when using the A-V difference equation in our study, the recovery clearance method
indicated a virtually null contribution from dialysis to its elimination. A low dialyzability
was similarly expected for bisoprolol after consulting the dialysis of drugs guidelines and
various peer-reviewed articles (Table 1.3). Surprisingly, our study indicates that
bisoprolol is moderately dialyzable regardless of the method used to determine its
clearance rate. Kanegae et al. (1999) found a comparable dialytic clearance of 50.8
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mL/min for patients who were also prescribed polysulfone-based dialyzer membranes.
This finding of moderate dialyzability is reflective of bisoprolol’s intermediate
physicochemical properties as compared to carvedilol and atenolol. Specifically,
bisoprolol has a mild degree of protein binding (30%) as well as balanced lipophilic and
hydrophilic components in its molecular structure (Buhring et al., 1986; Leopold, 1986).
Further evidence showing the impact that modern dialyzers have on drug
dialyzability can be derived from comparisons of elimination half-life. For severe renal
impairment patients not yet receiving dialysis, the half-life of atenolol, bisoprolol,
carvedilol and metoprolol are approximately 70, 24, 7 and 5 hours, respectively (Flouvat
et al., 1980; Jordo et al., 1980; Kirch et al., 1987; Gehr et al., 1999). Although very few
studies have evaluated dialytic clearance, the half-life for these beta blockers have been
previously reported for patients on older conventional dialyzers. The half-life of atenolol
is shortened to only 7 hours during conventional hemodialysis (Campese et al., 1985; Fox
and Investigators, 2003), which was found to be further reduced to 3.9 hours due to the
use of modern dialyzers in our study. In order to maintain the pharmacological effect of
atenolol when patients transition from ESRD to dialysis, an increase in dosage is required
and changing intake of atenolol to a post-dialysis period should be considered. Plasma
concentrations of bisoprolol in patients using a polysulfone dialyzer were reduced by
25% during hemodialysis (Kanegae et al., 1999), similar to what we determined in our
study. The resulting half-life was 7 hours—over 70% shorter than what is observed in
non-dialysis ESRD patients. For carvedilol and metoprolol, their half-life in CKD
patients do not differ largely from the values reported in patients with normal functioning
kidneys (Regardh and Johnsson, 1980). However, the modern hemodialyzers used in this
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study did result in a minor decrease in metoprolol half-life, which corresponds to more
than half of the drug being eliminated within a 4 hour dialysis session.
Plasma concentration-time profiles of each beta blocker during the hemodialysis
session were evaluated to assess drug exposure. The variability in plasma drug levels at
each time point between patients was noticeably lower for atenolol than other beta
blockers. This disparity may be explained by differences in the route of elimination for
each drug. Little to none of atenolol clearance can be attributed to hepatic metabolism,
suggesting that dialysis is the primary mechanism of atenolol removal in kidney failure
patients (AstraZeneca Canada Inc., 2011). Since the hemodialysis treatment plan and
dialyzer membranes prescribed between subjects were similar, the more consistent drug
levels observed were as expected. In contrast, metoprolol is extensively metabolized by
the drug metabolizing enzyme, cytochrome P450 2D6 (CYP2D6), with only 5% of the
drug eliminated through renal excretion (Regardh and Johnsson, 1980). Interindividual
differences in plasma concentration of metoprolol may be due to the large phenotypic
variability in CYP2D6 genotype and the associated categorizations of people into poor,
intermediate, extensive or ultra-rapid drug metabolizers (Zanger et al., 2004). Rau et al.
(2002) demonstrated that poor and intermediate metabolizers on long-term metoprolol
treatment had plasma concentrations 6- and 4-fold higher than extensive metabolizers,
respectively. A recently completed meta-analysis of CYP2D6 phenotypes similarly
showed that poor metabolizers had a 5- and 13-fold increase in metoprolol exposure as
compared to extensive and ultra-rapid metabolizers, respectively (Blake et al., 2013).
Despite this variability in pharmacokinetics, there still exist controversial findings as to
whether CYP2D6 genotyping can offer clinical benefit to metoprolol dosing in patients.
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Shin and Johnson (2007) have stated that the overall pharmacological efficacy and
toxicity of metoprolol are not influenced by CYP2D6 genotype, while Swen et al. (2011)
have reported a necessity to alter metoprolol dosage in heart failure patients depending on
their CYP2D6 metabolizer phenotype. In our study, individual plasma profiles of study
subjects demonstrated good correlation with a one-phase decay model, reaffirming that
metoprolol is highly cleared by hemodialysis.
Bisoprolol has a balanced mechanism of clearance with equal contributions from
both renal and non-renal pathways (Leopold et al., 1982). The main drug metabolizing
enzymes involved in bisoprolol elimination are CYP3A4 and CYP2D6 (Horikiri et al.,
1998). However, variations in oral clearance, apparent volume of distribution, and plasma
concentration are not well correlated with CYP2D6 genotypes (Nozawa et al., 2005;
Taguchi et al., 2005). An in vitro study using intestinal epithelial cells indicates
temperature and pH dependent alterations in the rate and extent of bisoprolol uptake
(Ishida et al., 2013). These findings offer one possible explanation for interindividual
variation of bisoprolol levels, but future clinical studies investigating differences in drug
bioavailability are required. Lastly, dialysis plays a very minor role in the clearance of
carvedilol for ESRD patients whereas hepatic metabolism accounts for more than 98% of
carvedilol disposition (Auro Pharma Inc., 2013). In particular, the diversity of genetic
polymorphisms for the enzymes responsible for aromatic ring oxidation (CYP2D6 and
CYP2C9) and glucuronidation (UGT2B7) have been shown to be important factors in the
interindividual pharmacokinetic variability of carvedilol (Takekuma et al., 2007; Pan et
al., 2016).
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As important as dialytic clearance may be, non-dialytic mechanisms for clearance
(e.g. hepatic or biliary excretion) still have a large role in dictating drug elimination
during hemodialysis. In particular, almost all of carvedilol clearance was a result of nondialytic pathways. Metoprolol had a considerably higher total clearance as compared to
all other beta blockers, most likely explained by combinations from both high hepatic
metabolism and high dialytic clearance. Atenolol and bisoprolol required the largest postdialysis dose at nearly 23% (11 mg) and 40 % (2 mg) of their initial prescribed dose. For
healthcare professionals determining the supplemental dose required to maintain patients
within a therapeutic window, both dialytic and non-dialytic means of elimination must be
considered. However, regulatory agencies should consider invoking specifications for
highly dialyzable drugs to be taken only after dialysis in order to overcome the need for
supplemental doses. These additional pharmacokinetic parameters that we examined have
never been incorporated in previous dialyzability studies. Nonetheless, other groups
investigating drug dialyzability can implement these equations to determine clinicallyrelevant supplemental information.

4.1.2

Retrospective Cohort Study
A published study by Weir et al. (2015) has demonstrated the impact that drug

dialyzability can have on clinical outcomes. Atenolol, metoprolol, and acebutolol were
classified as “high dialyzability” beta blockers, while bisoprolol and propranolol were
categorized as “low dialyzability” drugs. Hemodialysis patients prescribed highly
dialyzed beta blockers exhibited a significantly increased risk for all-cause mortality and
ventricular arrhythmia. Conversely, patients not requiring dialysis demonstrated no
difference in risk for adverse clinical outcomes between dialyzability groups, as
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expected. These findings strengthen the idea that beta blocker dialyzability should be
considered when constructing future treatment plans. One limitation described by Weir et
al. (2015) was that classification of dialyzability was based on either data from
conventional dialysis membranes or solely on the physicochemical characteristics of the
drugs. Indeed, results from our dialyzability study have since recognized that bisoprolol
is actually moderately dialyzed, although it has been previously classified as nondialyzed (Table 1.3). In addition, patients administered carvedilol were omitted from the
study due to its limited indications required for prescription in Ontario. Our current data
creation plan comparing dialysis patients on carvedilol with those on metoprolol has
since been submitted and approved by programmers, and is currently in queue for data
analysis (Appendix G). The study objectives and design have been further described in
Appendix F. It is unfortunate that a large delay in programming has made this data
unavailable for incorporation into this thesis. Although the programming has taken longer
than expected, we also delayed the start of the retrospective cohort study until all patient
data from the dialyzability study was complete. We felt this was important since our
findings in terms of dialyzability were essential in the data creation plan of the
retrospective study.

4.2

Research Significance
Despite one study having previously shown that bisoprolol is removed during

hemodialysis (Kanegae et al., 1999), it is still widely assumed that this beta blocker is
minimally dialyzed. The findings from this clinical pharmacokinetic study demonstrate
conclusively that bisoprolol should be re-categorized as having moderate dialyzability.
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Although estimations of drug dialyzability can be made based on physicochemical
properties, this unexpected discovery highlights the importance of conducting formal,
experimental studies to definitively characterize drug dialyzability. CKD patients of all
stages, with and without dialysis, must be better represented in the drug discovery
process in order to optimize pharmacotherapy in this growing population. This has been
acknowledged thus far by the FDA through the implementation of the 1998 FDA Renal
Guidance and the current 2010 draft guidance that is pending implementation. A recent
survey conducted by Matzke et al. (2015) illustrates the positive impact on drug
development created by the 1998 Renal Guidance. From 1999–2010, 71.6% of new
investigational drugs conducted appropriate renal studies—a significant improvement
from 51.6% in the two year span of 1996–1997 (Matzke et al., 2015). As the 1998 Renal
Guidance did not emphasize renal studies for non-renally cleared drugs, the involvement
of CKD patients were more likely observed in drugs characterized by renal excretion
(89.6%) as compared with drugs that primarily display non-renal elimination (65.8%)
(Matzke et al., 2015). Nearly 50% of NCEs with low renal clearance exhibited substantial
pharmacokinetic changes. However, only one-third of those NCEs resulted in dosage
recommendations and proper labeling. With greater emphasis in the 2010 draft guidance
to complete renal and dialyzability studies in drugs with non-renal clearance, these results
provide an encouraging outlook for future NCEs to standardize the incorporation of CKD
patients in pharmacokinetic studies. In turn, accurate clinical information to describe
which drugs require a supplemental dose can be determined, and recommendations can
be made on preferred medication choices in hemodialysis patients for drugs in the same
class.
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Current clinical practice guidelines outlined by the National Kidney Foundation
make no recommendations on which beta blocker should be prescribed to CKD and
dialysis patients. Beta blockers have become a cornerstone treatment to battle
cardiovascular disease due to their widespread applicability—from treating heart failure,
to post myocardial infarctions, to angina (Kidney Disease Outcomes Quality Initiative,
2004). The dialyzability of beta blockers found in our study can be implemented in future
clinical practice guidelines and disseminated to healthcare professionals in order to help
their drug selection process. One of the current recommendations by the National Kidney
Foundation is to choose a simplified antihypertensive regimen with only a single daily
dose requirement if possible (Kidney Disease Outcomes Quality Initiative, 2004). We
now know that atenolol, bisoprolol, and metoprolol are all cleared during hemodialysis
which indicates that patients may require a post-dialysis dose for their therapy to
maintain levels required for efficacy. Conversely, carvedilol removal by dialysis is
negligible. Due to renal excretion accounting for less than 2% of its elimination, plasma
levels of carvedilol do not accumulate in any form of renal impairment (Deetjen et al.,
1995). These combined findings suggest that no dosage adjustments are required for
carvedilol when patients progress from normal to reduced kidney function, even if renal
replacement therapy is necessary (Miki et al., 1991; Gehr et al., 1999). Hence, the
preferential selection of carvedilol over other beta blockers should be considered.
In agreement, the strongest evidence in support of administering carvedilol as
opposed to other beta blockers is due its proven efficacy in ESRD patients. Carvedilol is
the only beta blocker and one of the only antihypertensive drugs that has been tested in
prospective randomized clinical trials in dialysis patients. Cice et al. (2001) demonstrated
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that for hemodialysis patients with dilated cardiomyopathy, a year-long administration of
carvedilol reduces left ventricular volumes and improves overall cardiac function. This
cohort of patients was subsequently followed for another 12 months to assess the effect of
carvedilol on mortality and morbidity (Cice et al., 2003). When compared to placebocontrolled patients, carvedilol significantly reduced all-cause mortality, cardiovascular
mortality, and all-cause hospitalizations. Fatal myocardial infarctions and strokes—two
main causes for cardiovascular death in ESRD patients (Saran et al., 2016)—were also
considerably reduced in carvedilol-treated subjects.
Although carvedilol is typically reserved for patients with symptomatic heart
failure, it may be worth considering expanding the application of carvedilol in dialysis
patients. Based on its ideal pharmacokinetic qualities in CKD patients and previous
clinical trials indicating its strength to improve patient morbidity, we are hopeful that the
administration of carvedilol will become more liberal.

4.3

Limitations and Future Directions
When conducting pharmacokinetic studies to categorize drug dialyzability, the

recovery clearance method is widely accepted as the gold-standard approach. One
limitation for using this method is the requirement for a sensitive technique when
measuring very low drug concentrations in large volumes of dialysate. Despite us
concentrating samples 100-fold and our UPLC-MS providing accurate, sensitive
detection of small molecules, some dialysate samples containing carvedilol were below
our LLOQ. However, negligible dialytic clearance of the beta blocker may have resulted
in samples having virtually no carvedilol for detection.
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Subjects enrolled in our study had dialysis durations varying from 3 to 4 hours.
Patient variability in dialysis time result in differences in how much drug is remaining at
the end of dialysis. However, the dialytic clearance values are not affected by shorter or
longer dialysis durations since the recovery clearance equation (Equation 2) takes the
ratio of amount dialyzed over total drug exposure. Regarding study design, a single oral
dose prescription as used in our study may not produce pharmacokinetic parameters
reflective of patients on long-term beta blocker therapy. For instance, dialytic clearance is
dependent on dialysis prescription factors including blood flow rate, dialysate flow rate,
and ultrafiltration rate—all of which can vary from one dialysis session to another.
Despite this, the overall categorization of a drug’s dialyzability is not expected to change
significantly. One proposed future study can examine the dialytic clearance of beta
blockers for dialysis patients at steady state. Additionally, plasma concentration of beta
blockers at steady state should be compared between normal renal function and chronic
hemodialysis patients. If drug dialyzability is an important determinant of therapeutic
efficacy, we expect that highly dialyzed drugs would exhibit a substantially lower steady
state concentration in subjects on dialysis while poorly dialyzed drugs will show no
difference in plasma levels.
Another caveat in our study was the use of literature values to determine
additional pharmacokinetic parameters (VD, FU, and kE). The studies used had small
sample sizes which may produce values that are not representative for all CKD patients.
In addition, the supplemental dose calculated for each beta blocker did not account for
post-dialysis rebound of the drugs. Future study designs will attempt to include more
sample collection at time points after the dialysis session to characterize any potential
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drug distribution out of tissue. Nonetheless, these equations still provide the framework
to determine clinically-relevant parameters for any subsequent dialyzability studies.
The unexpected result of bisoprolol having moderate dialyzability prompted us to
review other drugs prescribed to subjects during the duration of the study. We compiled a
list of different drug classes of interest including narcotics (morphine and codeine),
vitamin D supplements (alfacalcidol and calcitriol), cardiovascular medications (ACE
inhibitors, ARBs, CCBs and statins), antipsychotics (lorazepam, diazepam, gabapentin,
etc.), anticoagulants, and proton pump inhibitors (lansoprazole and rabeprazole).
Morphine, codeine, lansoprazole, and warfarin were detected in patient dialysate samples
despite the latter 3 drugs being listed as not dialyzble (Figure 4.1) (Baillie and Mason,
2013). This finding confirms the notion that studies involving conventional hemodialysis
have become obsolete and drug dialyzability must be further investigated to optimize
pharmacotherapy in ESRD patients. Looking forward, similar dialyzability studies should
be conducted for other classes of cardiovascular medications (ACE inhibitors, ARBs,
CCBs and anticoagulants) in hopes of improving the overall management of cardiac
disease in dialysis patients. Results from both present and future investigations will be
disseminated to practitioners and regulatory agencies for knowledge translation into
clinical practice guidelines.
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(B)

(E)
(A)
(D)

Figure 4.1. Select drugs of interest detected in subject dialysate samples.
A list of drugs of interest was created after reviewing the prescription record of subjects
during the study period. Morphine (A), codeine (B), lansoprazole (C), and warfarin (D)
were

detected

in

patient

dialysate

samples

using

ultra-performance

liquid

chromatography coupled to quadrupole time-of-flight mass spectrometry (UPLCQToFMS).
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4.4

Conclusions
In much of recent literature, adequacy of dialysis for ESRD patients has been

erroneously assumed to be synonymous with adequacy of patient care (National Kidney
Foundation, 2015). This concept and approach to healthcare is inaccurate. The overall
purpose for renal replacement therapy is to improve the quality of life and prognosis for a
vulnerable, globally-growing population. However, many aspects of the treatment plan
for ESRD patients are established prior to the renal replacement strategy and are
independent or only partially-dependent on dialysis itself. For example, the dosage
regimen for drug therapy is often devised in earlier stages of CKD but become
extensively intertwined with the daily life of dialysis patients to combat cardiovascular
complications and other comorbidities. As such, the importance of dialyzability research
has been identified by an international guideline committee for renal disease, Kidney
Disease | Improving Global Outcomes (KDIGO) (Atkinson and Umans, 2010; Dager,
2010). When drugs are approved for use in the general population, they must undergo
extensive pharmacokinetic evaluation for determination of renal clearance among other
parameters. Despite the widespread use of cardiovascular medications in patients
receiving hemodialysis and the clear difference between dialytic and renal excretion,
there still remains a paucity of data describing drug elimination during dialysis. In this
study, we were able to definitively categorize the four most commonly prescribed beta
blockers in Ontario into high (atenolol, metoprolol), moderate (bisoprolol) and low
(carvedilol) dialyzability drug groups. Clinicians and scientists are encouraged to
continue conducting pharmacokinetic studies to characterize drug dialyzability and
provide more evidence on the necessity of including dialysis patients in drug
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development. When considering study design for future dialyzability studies, it would be
ideal to conduct studies in both single-dose and steady-state dosing conditions, use the
superior recovery clearance method, and confirm that drug concentrations remain in the
therapeutic window following dialysis to ensure efficacy. The clear implications that drug
dialyzability has for the efficacy of pharmacotherapy will hopefully improve quality of
care and prognosis for all patients receiving chronic hemodialysis.
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Appendix C: Supplementary Information
Supplementary Table C1. Dialyzability of angiotensin converting enzyme (ACE) inhibitors.
Dialyzability Data
ACE Inhibitor

Fosinoprilat

Ramiprilat

Enalaprilat

Lisinopril

Perinoprilat

Molecular
Weight
(Daltons)

435

388

348

405

340

Protein
binding
(%)

Volume of
distribution
(L/kg)

99

“very
small”

56

50

<1

15

Clearance
during
hemodialysis
(ml/min)

Reference

Recovery method
Single dose
Dialyzer: cellulose
QD: 550 ml/min
QB: 250 ml/min

4

(Gehr et al.,
1993)

A-V Difference method
Multiple doses
Dialyzer: cellulose
QD: 500 ml/min
QB: 250-300 ml/min

21

A-V Difference method
Single dose
Dialyzer: cellulose
QD: 500 ml/min
QB: 250-300 ml/min

32

A-V Difference method
Multiple doses
QB: 230 ml/min

39

A-V Difference method
Single dose
Dialyzer: cellulose
QD: 500 ml/min
QB: 300 ml/min

68

A-V Difference method
Multiple doses
Dialyzer: cellulose
QD: 500 ml/min
QB: 300 ml/min

57

2.4

A-V Difference method
Multiple doses
Dialyzer: ?
QD: ?
QB: 230 ml/min

40

0.2

A-V Difference method
Single dose
Dialyzer: polysulfone
QD: 500 ml/min
QB: 300 ml/min
A-V Difference method
Multiple doses
Dialyzer: polysulfone
QD: 500 ml/min
QB: 300 ml/min
A-V Difference method
Single dose
Dialyzer: cellulose
triacetate
QB: 200 ml/min
A-V Difference method
Multiple doses
Dialyzer: polysulfone
QD: ?
QB: 200 ml/min

1.2

1.7

Specified
Dialyzability Testing
Conditions*

(Fillastre et
al., 1996)

(Kelly et al.,
1988)

(Fruncillo et
al., 1987)

(Kelly et al.,
1988)

62
(Guérin et
al., 1993)
72

66

(Verpooten
et al., 1991)

108

(Yamada et
al., 2003)

99

Benazeprilat

396

95

0.1

No data

Quinaprilat

428

97

0.4

A-V Difference method
Multiple doses
Dialyzer: polysulfone
QD: ?
QB: 200 ml/min

Trandolaprilat

402

75

0.3

No data

No data

-

52

(Yamada et
al., 2003)

No data

-

* Clearance of a drug during hemodialysis can be determined by the Recovery Method, in which drug
removal is determined from the total spent dialysate, or by the A-V Difference Method, in which clearance is
calculated with the Fick Equation using the difference in drug concentrations between the arterial (A) and
venous (V) limbs of the dialysis machine and the blood flow rate.
Abbreviations: QD, dialysate flow rate; QB, blood flow rate; UF, ultrafiltration rate.
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Supplementary Table C2. Dialyzability of study angiotensin II receptor blockers (ARBs).
Dialyzability Data
ARB

Molecular
Weight
(Daltons)

Protein
binding
(%)

Volume of
distribution
(L/kg)

Candesartan

440

99

0.13

Irbesartan

429

90

0.75

Losartan

423

99

0.49

Olmesartan

447

99

0.24

Telmisartan

515

99

>7

Valsartan

436

95

0.24

Specified
Dialyzability Testing
Conditions*
A-V Difference method
Multiple doses
Dialyzer: polysulfone
QD: 500 ml/min
QB: 400 ml/min
A-V Difference method
Multiple doses
Dialyzer: ?
QD: ?
QB: ?
A-V Difference method
Single dose
Dialyzer: polysulfone
QD: 500 ml/min
QB: 400 ml/min
A-V Difference method
Single dose
Dialyzer: polysulfone
QD: ?
QB: ?
Recovery method
Single dose
Dialyzer: olysulfone
QD: ?
QB: ?

No data

Clearance
during
hemodialysis
(ml/min)

Reference

1.5

(Pfister et al.,
1999)

“Not removed”

(Sica et al.,
1997)

“Approximately
zero”

(Sica et al.,
2000)

“Not removed”

(Tanaka et al.,
2009)

“Very little
removed”

(Stangier et
al., 2000)

No data

-

* Clearance of a drug during hemodialysis can be determined by the Recovery Method, in which drug
removal is determined from the total spent dialysate, or by the A-V Difference Method, in which clearance is
calculated with the Fick Equation using the difference in drug concentrations between the arterial (A) and
venous (V) limbs of the dialysis machine and the blood flow rate.
Abbreviations: QD, dialysate flow rate; QB, blood flow rate.
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Supplementary Table C3. Dialyzability of calcium channel blockers.
Dialyzability Data
Calcium
Channel
Blocker

Amlodipine

Diltiazem

Molecular
Weight
(Daltons)

Protein
binding
(%)

Volume of
distribution
(L/kg)

567.1

98

0.3

451

70-80

0.07-0.15

Felodipine

384.2

>99

0.15

Nicardipine

516

98

0.6-6.8

Nifedipine

Verapamil

346.3

491.1

88-95

90

0.75-1.5

3.8-5

Specified Dialyzability
Testing Conditions*
One time concentration
of dialysate
Dialyzer: ?
QD: ?
QB: ?

No Data
A-V Difference method
Single oral dose
followed by single IV
dose
Dialyzer: cellulose
QD: 500 ml/min
QB: 200 ml/min
No Data
A-V Difference method
Single dose
Dialyzer: 1.2 m2
cuprophane
QD: 500 ml/min
QB: 200 ml/min
A-V Difference method
Single dose
Dialyzer: cuprophane
QD: ?
QB: 250-280 ml/min
Recovery method
Multiple doses
Dialyzer: cuprophane
QD: 500
QB: 200 ml/min

Clearance
during
hemodialysis
(ml/min)
No clearance
data, but
concentration
in dialysate
very low

Reference

(Kungys et
al., 2003)

No Data

-

Negligible, but
inactive
metabolites
with clearance
of 8.4-13.8

(Buur et
al., 1991)

No data

-

2.8

(Martre et
al., 1985)

Negligible

(Hanyok et
al., 1988)

Negligible

(Shah and
Winer,
1985)

* Clearance of a drug during hemodialysis can be determined by the Recovery Method, in which drug
removal is determined from the total spent dialysate, or by the A-V Difference Method, in which clearance is
calculated with the Fick Equation using the difference in drug concentrations between the arterial (A) and
venous (V) limbs of the dialysis machine and the blood flow rate.
Abbreviations: QD, dialysate flow rate; QB, blood flow rate, IV, intravenous.
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Supplementary Table C4. Dialyzability of antiplatelet agents.
Dialyzability Data
Antiplatelet
Agent

Acetylsalicylic
Acid (Aspirin)

Molecular
Weight
(Daltons)

180

Protein
binding
(%)

99.5

Volume of
distribution
(L/kg)

0.15-0.20

Specified
Dialyzability Testing
Conditions*

Clearance
during
hemodialysis
(ml/min)

Reference

A-V Difference method
Dialyzer: ?
QD: ?
QB: 200 ml/min

86**

(Jacobsen
et al.,
1988)

A-V Difference method
Dialyzer: cuprophane
QD: ?
QB: 100 ml/min

30-35**

(Doolan et
al., 1951)
(Spritz et
al., 1959)

A-V Difference method
Dialyzer: cuprophane
QD: ?
QB: 250 ml/min

80**

(Kallen et
al., 1966)

Dipyridamole

505

91-99

1.0-2.5

No Data

No Data

-

Clopidogrel

321

98

-

No Data

No Data

-

Prasugrel

373

98

-

No Data

No Data

-

Negligible

(Bern et
al., 1980)

Sulfinpyrazone

404

98

0.35

Single dose
Dialyzer: cuprophane
QD: ?
QB: ?

Ticagrelor

340

>99.7

1.25

No Data

No Data

-

Ticlopidine

264

98

-

No Data

No Data

-

* Clearance of a drug during hemodialysis can be determined by the Recovery Method, in which drug
removal is determined from the total spent dialysate, or by the A-V Difference Method, in which clearance is
calculated with the Fick Equation using the difference in drug concentrations between the arterial (A) and
venous (V) limbs of the dialysis machine and the blood flow rate.
** Data derived from overdose settings
Abbreviations: QD, dialysate flow rate; QB, blood flow rate.
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Supplementary Table C5. Dialyzability of anitcoagulants.
Dialyzability Data
Oral
Anticoagulants

Molecular
Weight
(Daltons)

Protein
binding
(%)

Volume of
distribution
(L/kg)

Specified
Dialyzability
Testing
Conditions*

Clearance
during
hemodialysis
(ml/min)

Reference

31% drop in
warfarin
concentratio
n during
dialysis

(Ifudu and
Dulin, 1993)

Warfarin

308

99

0.14

A-V Difference
method
Multiple
Dialyzer:
sulphonated
cellulose acetate
QD: 500 ml/min
QB: 300 ml/min

Acenocoumarol

343

98.7

0.18

No Data

No Data

-

Apixaban

459

>90%

0.3

No Data

18**

-

10 ng/mL
per hour

(Chang et al.,
2013)

Dabigatran

Rivaroxaban

627.7

436

35

0.85-1.0

92-95

0.7

A-V Difference
method
Steady State
Dialyzer: “highflux”
QD: ?
QB: 350 mL/min
A-V Difference
method
Multiple doses
Dialyzer: Polyflux
PF
QD: 700 mL/min
QB: 200 mL/min
A-V Difference
method
Multiple Dose
Dialyzer: Polyflux
PF
QD: 700 mL/min
QB: 400 mL/min
A-V Difference
method
Multiple doses
Dialyzer:
polysulfone
QD: 500 mL/min
QB: 400 mL/min

161
(Khadzhynov
et al., 2013)
241

0

(De Vriese et
al., 2015)

Low Molecular Weight Heparin
Enoxaparin

1117

80

0.07

No Data

No Data

-

Dalteparin

6000

-

0.04

No Data

No Data

-

Nadroparin

4300

-

0.05

No Data

No Data

-

No Data

No Data

-

72.8§

(Robson,
2000)

Injectable Direct Thrombin Inhibitors
Desirudin

6964

-

0.26

Bivalirudin

2180

-

0.2

Steady State
Dialyzer: ?
QD: ?
QB: ?
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Argatroban

509

54

0.17

Recovery method
Multiple doses
Dialyzer: Cellulose
Triacetate
QD: ?
QB: ?

49§

(Murray et al.,
2004)

Population
pharmacokinetics
model
Multiple doses
Dialyzer: High flux
QD: 500 mL/min
QB: 388 mL/min

9.8

(Kalicki et al.,
2007)

No Data

-

Injectable Factor Xa Inhibitors

Fondaparinux

1730

94

0.1 – 0.16

Danaparoid

~6000

-

0.1

No Data

* Clearance of a drug during hemodialysis can be determined by the Recovery Method, in which drug
removal is determined from the total spent dialysate, or by the A-V Difference Method, in which clearance is
calculated with the Fick Equation using the difference in drug concentrations between the arterial (A) and
venous (V) limbs of the dialysis machine and the blood flow rate.
** From Product Monograph.
§ Normalized to 70 kg body weight.
Abbreviations: QD, dialysate flow rate; QB, blood flow rate
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Supplementary Table C6. Dialyzability of cholesterol-lowering medications.
Dialyzability Data
Cholesterol
Lowering
Drugs

Atorvastatin

Rosuvastatin

Simvastatin

Pravastatin

Molecular
Weight
(Daltons)

558

482

419

425

Protein
binding
(%)

≥98

88

95

50

Volume of
distribution
(L/kg)

Specified Dialyzability
Testing Conditions*

381

Single oral dose
Dialyzer: ?
QD: ?
QB: ?

134

A-V Difference method
Steady State
Dialyzer: ?
QD: ?
QB: ?

--

No Data

411

98

Reference

Negligible

(Lins et al.,
2003)

34.8 for
Rosuvastatin
<42 for
metabolites
No Data

A-V Difference method
Multiple doses
Dialyzer: Cellulose acetate
QD: ?
QB: 200-250 mL/min

38-55

Recovery method
Multiple doses
Dialyzer: Cellulose acetate
QD: ?
QB: 200-250 mL/min

49-81

(Birmingha
m et al.,
2013)

-

(Gehr et al.,
1997)

56

A-V Difference method
Dialyzer: pulysulfone
QD: 500 mL/min
QB: 180-300 mL/min

Fluvastatin

Clearance
during
hemodialysis
(ml/min)

Negligible

(Ichimaru et
al., 2004)

Recovery method
Dialyzer: ?
QD: ?
QB: ?

Negligible

(Appel‐
Dingemanse
et al., 2002)

Lovastatin

405

>95

-

No data

No data

-

Ezetimibe

409

>90

-

No Data

No data

-

* Clearance of a drug during hemodialysis can be determined by the Recovery Method, in which drug
removal is determined from the total spent dialysate, or by the A-V Difference Method, in which clearance is
calculated with the Fick Equation using the difference in drug concentrations between the arterial (A) and
venous (V) limbs of the dialysis machine and the blood flow rate.
Abbreviations: QD, dialysate flow rate; QB, blood flow rate.
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Appendix D: Screening Criteria for Subject Enrolment
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Appendix E: Letter of Information
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Appendix F: Effect of Dialyzability on Clinical Outcomes
Aim: Evaluate the effect of beta blocker dialyzability on risk for all-cause mortality
and cardiovascular outcomes.
After categorizing beta blockers into their dialyzability group, a propensitymatched, population-based retrospective cohort study was designed using the linked
health administrative databases of Ontario, Canada (Appendix F). To assess the effect of
dialyzability on clinical adverse outcomes, chronic hemodialysis patients on a poorly
dialyzed beta blocker (carvedilol) were compared to those on a highly dialyzed beta
blocker (metoprolol).
A recent study by Weir et al. (2015) has shown that elderly hemodialysis patients
prescribed highly dialyzed beta blockers had a significant 1.4 fold increase in the risk for
all-cause mortality as compared to patients on poorly dialyzed beta blockers. One
criticism expressed for this previous study was the omission of carvedilol-treated patients
(Shroff and Herzog, 2015). Carvedilol is the only beta blocker with a prospective clinical
trial to prove its efficacy in subjects receiving dialysis (Cice et al., 2003). Consequently,
the data creation plan for our study compares hemodialysis patients on carvedilol to those
on metoprolol. Due to the low dialyzability of carvedilol, we expect that patients
receiving this drug will have a comparatively better survival benefit and a decreased risk
for cardiovascular outcomes.

Methods
Study design
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A provincial-wide retrospective matched cohort study was conducted using health
administrative data from April 1, 2002 to September 30, 2014 on all chronic
hemodialysis patients who were older than 66 years. One cohort of subjects included only
those with evidence of continuous carvedilol use (low dialyzability group), and the other
included those with only continuous use of metoprolol (high dialyzability group).
Subjects were propensity matched between the two dialyzability cohorts and compared
for their risk of all-cause mortality and adverse cardiovascular outcomes using odds
ratios. We collected and analyzed all exposure, outcome and covariate data according to a
predefined protocol. The study was approved by the institutional review board at
Sunnybrook Health Sciences Centre, Toronto, Canada, and its design and reporting
follow the Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) statement guidelines (von Elm et al., 2008).

Setting
Ontario is the most populated province in Canada with nearly 13 million residents
in 2011—1.9 million of whom were 65 years of age or older (Statistics Canada, 2012).
The Ontario Health Insurance Plan (OHIP) provides all residents of Ontario with
universal access to physician and hospital services. Additionally, the Ontario Drugs
Benefit (ODB) program allows access for those who are 65 years and older to universal
coverage for many prescription medications. The single health insurance payer in Ontario
and an emigration rate of less than one percent per year produces a database of health
administrative information that is both comprehensive and stable (Ontario Ministry of
Finance, 2016).

Sources of Administrative Data
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We used Ontario’s health administrative data housed at the Institute of Clinical
Evaluative Sciences (ICES) to assemble a cohort of patients receiving chronic
hemodialysis and determined the impact of dialyzability on mortality and cardiovascular
outcomes. We identified patients, exposures, outcomes and covariates using four linked
datasets: (1) Ontario Drug Benefits (ODB) Database. Information on outpatient
medications in the ODB formulary was used to ascertain drug-related baseline
characteristics and beta blocker exposure, a covariate in our regression model. (2)
Canadian Institute of Health Information (CIHI) Discharge Abstract Database (DAD).
This database was used to identify patient baseline characteristics, hospital admission for
cardiovascular complications, and potential confounding diagnoses. The causes for
hospitalizations were determined based on the codes found in the ninth and tenth editions
of the International Classification of Disease (ICD-9 and ICD-10). The accuracy of the
codes in these databases has been assessed for many diagnoses (Jong et al., 2003;
Juurlink et al., 2006). (3) Ontario Health Insurance Plan (OHIP) Claims History
Database. Most physicians submit billing claims with diagnoses codes that contain
information on inpatient, outpatient and laboratory services. This OHIP database
ascertained cardiovascular procedures and confounding variables to be included in our
regression models. (4) Registered Persons Database (RPDB). The RPDB captures
information regarding sex, date of birth, postal code and vital status. This database was
used to confirm patient mortality. Relative to the CIHI-DAD, the RPDB has a sensitivity
of 94% and a positive predictive value of 100% for flagging in-hospital mortality (Jha et
al., 1996).

Study Population and Cohorts
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In order to ensure that the cohorts of patients were administered one of the two
beta blockers during the entirety of their hemodialysis treatment, physician billing
records from April 1, 2002 to March 31, 2015 were first used to determine all patients
who were treated with long-term hemodialysis. The index date used to identify eligible
patients was the date of the first prescription for carvedilol or metoprolol. Subject
enrollment was restricted to those older than 66 years old. This minimal age limitation
was implemented to guarantee at least 1 year of drug use data since Ontario citizens over
the age of 65 years receive universal coverage for prescription medications. Following
the age restriction, patients were further filtered by excluding those with greater than one
beta blocker prescription and those who did not fill a prescription for one of the two study
beta blockers. To identify beta blocker initiation that occurred while receiving
hemodialysis, patient prescriptions that were not preceded within 30 days by a long-term
hemodialysis code (H540, H740, G325, G326, G860, G862, G863 and G866) were
excluded. Furthermore, patients were excluded if they filled any beta blocker prescription
within 120 days of their first filled prescription while on hemodialysis. This ensured that
enrolled patients were new users of the beta blockers.
Beta blocker dialyzability was the main exposure. Based on findings from the
pharmacokinetic, 4-way crossover study (Figure 3.3), patients prescribed carvedilol were
categorized into the “low dialyzability” exposure group. Conversely, those prescribed
metoprolol were classified as the “high dialyzability” control group.

Propensity Score Computation and Matching
For the hemodialysis cohort, prevalence of baseline characteristics between the
high and low dialyzability patient groups was compared. Following this comparison,
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carvedilol patients were matched to those on metoprolol in a one-to-two ratio based on
age (± 2 years), sex, and propensity score (±0.2 SD). Patients were matched without
replacement such that unexposed patients who have been matched can no longer serve as
a candidate for comparison with another patient. Propensity score analyses mitigate the
effects of imbalances in baseline characteristics on estimates of risk (Rosenbaum and
Rubin, 1983). Propensity scores were computed using a logistic regression model in
which metoprolol use was the dependent variable. Independent variables for the study
included age, year of index, sex, Charlson and John Hopkins comorbidity scores,
comorbid conditions (abdominal aortic aneurysm, coronary artery disease, heart failure,
peripheral vascular disease, and stroke), general measures of comorbidity (duration of
dialysis and number of unique prescriptions within the last year), and concomitant
medications (ACE inhibitors, alpha blockers, ARBs, CCBs, diabetes drugs, digoxin, and
nitrates).

Outcome Measures
The primary outcome was all cause mortality identified using the RPDB. The
secondary outcome is a composite of myocardial infarction, heart failure or ventricular
arrhythmia as identified by their corresponding hospitalization outcome codes. All
outcomes were specified prior to data analysis and assessed up to 180 days after the index
beta blocker prescription. This period of follow-up was chosen on the basis of the
findings that the median (interquartile range) duration of continuous use was 471 (85–
646) days for high dialyzability beta blockers and 508 (78–752) days for low
dialyzability beta blockers. The shorter observation period of 180 days allows for a
decreased likelihood of dropout or crossover between exposure groups.
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Statistical Methods
The first analysis conducted in this study was to determine imbalances in baseline
characteristics between exposure groups using standardized differences. This metric
describes differences between group means relative to their pooled standard deviation.
An absolute standardized difference of a covariate that is less than 10% is
inconsequential, and a 0% difference indicates no imbalance between the two exposure
groups for that covariate. Standardized differences that are greater than 10% describe
significant imbalances between the cohorts in question (Mamdani et al., 2005; Austin,
2009). After propensity matching patients, comparisons between the two dialyzability
groups were conducted. Conditional logistic regression analyses were used to estimate
odds ratios and 95% confidence intervals (CIs). Odds ratios were subsequently
interpreted as relative risks (RRs), which is reasonable given the low incidence of
outcomes. All analyses were completed with SAS software, version 9.2 (SAS Institute
Inc., Cary, NC).

Results
Upon completion of the clinical pharmacokinetic study, we were able to
decisively conclude that dialysis has a negligible impact on the clearance of carvedilol,
while metoprolol is highly dialyzed. These categorizations of beta blocker dialyzability
were translated into our data creation plan developed for a provincial-wide retrospective
cohort study. Unfortunately, unforeseen delays in programming at the Institute of Clinical
Evaluative Sciences (ICES) have hindered completion of this study. Our study design has
been approved and is currently in sequence for data analysis. Hemodialysis patients in the
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high dialyzability group (metoprolol) are still expected to exhibit an augmented risk for
mortality and adverse cardiovascular outcomes as compared with those in the low
dialyzability group (carvedilol).
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Appendix G: Data Creation Plan – Beta blocker dialyzability:
Carvedilol
 Project Initiation
 This Section must be Completed Prior to Project Dataset(s) Creation
Beta blocker dialyzability: Carvedilol
Project Title:
Project TRIM number: 2016 0906 194 000
KDT
Research Program:
ICES Western
Site:
Insert Project Objectives as listed in the approved ICES Project
Project Objectives:
PIA
To determine whether outcomes are better with carvedilol (nondialyzable) compared to metoprolol (highly dialyzable) in
patients on hemodialysis.
The ICES Employee or agent who is responsible for creating the
ICES Project PIA
Initial Approval Date: Project Dataset(s) is responsible for ensuring there is an
approved ICES Project PIA and verifying the date of approval
prior to creating the Project Dataset(s)
2016-Mar-10
Principal Investigator
Matthew Weir
(PI):
Check the applicable
☐ ICES Student
☐ ICES Fellow
☐ ICES Postbox if the PI is an ICES
Doctoral Trainee ☐ Visiting Scholar
Student/Trainee
Name the Responsible ICES Scientist if the PI is not a Full
Responsible ICES
Status ICES Scientist
Scientist:
Amit Garg
All person(s) (ICES Analyst, Appointed Analyst, Analytic
Epidemiologist, PI, and/or Student) responsible for creating the
Project Dataset(s) and/or statistical analysis on the Research
Analytics Environment (RAE) and the date they joined the
project must be recorded
Stephanie Dixon, 519-685-8500 ext 55979,
2016-Jan-22
stephanie.dixon@ices.on.ca
All other Research Project Team Members (e.g., Research
Other ICES Project
Administrative Assistants, Research Assistants, Project
Team Members and
Managers, Epidemiologists) and the date they joined the project
date joined (list all):
must be recorded
Racquel Jandoc, 519-685-8500 ext 77849,
racquel.jandoc@ices.on.ca
2016-Jan-22
Danielle Nash, 519-685-8500 ext 55980,
danielle.nash@ices.on.ca
Confirmation that DCP The following individuals must confirm that the ICES Data
Project Team
Member(s) Responsible
for Project Dataset
Creation and/or
Statistical Analysis and
date joined (list all):
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 Project Initiation
 This Section must be Completed Prior to Project Dataset(s) Creation
provided for in this DCP is relevant (e.g., with respect to cohort,
is consistent with
timeframe, and variables) and required to achieve the Project
Project Objectives:
Objectives stated in the ICES Project PIA prior to initial Project
Dataset creation: 1) PI; 2) Responsible ICES Scientist if the PI
is not a Full Status ICES Scientist, or a second ICES Scientist or
the Scientific Program Lead if the PI is creating both the DCP
and the Project Dataset[s]; 3) ICES Research Practice Staff
creating the DCP; and 4) ICES Analytic Staff (ICES Employee
or agent responsible for creating the Project Dataset[s]). This
may be delegated either verbally or via e-mail.
2015-Feb-05
Principal Investigator: Matthew Weir ☒
Responsible ICES Scientist or Second
☒
2016-Apr-20
ICES Scientist/Lead: Amit Garg
ICES Research Practice Staff Creating
☒
2015-Feb-05
the DCP: Danielle Nash
ICES Analytic Staff: Stephanie Dixon ☒
2015-Feb-05
The person named (ICES staff) is accountable for ensuring that
Designated ICES
Research Practice Staff the approved ICES Project PIA, ICES Project PIA Amendments,
accountable for Project and DCP are saved on the T Drive, ensuring ICES Project PIA
Amendments are submitted as required, ensuring DCP
Documentation:
Amendments are documented, and sharing the final DCP with
the PI/Responsible ICES Scientist at project completion
Racquel Jandoc
DCP Creation Date and Date DCP was finalized
prior to Project Dataset(s) Name of person who created the
Author:
creation
DCP
Date
Name
2016-Apr-20
Matthew Weir
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 ICES Data
 This Section must be Completed Prior to Project Dataset(s) Creation
The ICES Employee or agent who is responsible for
creating the Project Dataset(s) must ensure that this list
includes only data listed in the ICES Project PIA
Changes to this list after initial ICES Project PIA
Mandatory for all datasets that
approval require an ICES Project PIA Amendment
are available by individual year
General Use Datasets – Health Services
Years (where applicable)
CIHI DAD
CIHI SDS
NACRS
ODB
OHIP
See list
General Use Datasets – Care Providers

1997-2015
1997-2015
1997-2015
2001-2015
1997-2015

IPDB
See list
General Use Datasets – Population

1997-2013

RPDB
See list
General Use Datasets – Coding/Geography

1997-2015

See list
See list
General Use Datasets - Facilities
See list
General Use Datasets - Other
See list
See list
Controlled Use Datasets
See list
See list
Other Datasets
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 Project Amendments and Reconciliation
Privacy Person who
Note that any changes to the list of
ICES Project PIA
approval submitted
ICES Data or Project Objectives
Amendment History
amendment
require an ICES Project PIA
(add additional rows as date
Amendment
needed):
Date
Name
Amendment
yyyy-mondd
Note that any DCP amendments
DCP Amendment
Person who
involving changes to the list of ICES
History (add additional
Date DCP made the DCP Data or Project Objectives require
rows as needed):
amended amendment
an ICES Project PIA Amendment
Date
Name
Amendment
yyyy-mondd
The person(s) creating the dataset and/or analyzing the data are
Date Programs/DCP
responsible for ensuring that the final DCP reflects the final
reconciled
program(s) when the project is completed
yyyy-mon-dd

 Project Cohort
Study Design
☐ Cohort study
☒ Matched cohort study
☐ Case-control study
☐ Cross-sectional study
☐ Other (specify):
Inclusion criteria:
Index Event /
1. Patients with evidence of at least 1 chronic hemodialysis
Inclusion Criteria
code (Appendix B) between April 1, 2002 to September
30, 2014, and
2. First evidence of one study drug during the same time
period
Index date:
First prescription for a study drug (Appendix A, DCLASS=
“S_BBC”, “S_BBM”)
Carvedilol (DCLASS= “S_BBC”) = 600
Estimated Size of
Metoprolol (DCLASS= “S_BBM”) = 1200 (2:1 matched to
Cohort
carvedilol patients)
(if known)
Description
Exclusions (in order) Step
1
Data cleaning:
a) Patients with missing or invalid IKN
b) Patients with missing or invalid age or sex data
c) Death on or before index date
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Project Cohort

2
3

4

5

6



d) Non-Ontario residents (individuals without an
RPDB variable “prdcddablk” beginning with “35”)
Patients ≤66 years old as of index date
Evidence of a hospital discharge or an emergency
department visit on or within ≤2 days prior to index date
(including index date)
No evidence of a chronic hemodialysis code in the 30
days prior to and including index date (this is intended to
eliminate patient who started beta blockers prior to
starting hemodialysis) (Appendix B)
Evidence of any study beta blocker prescription in the 120
days prior to index date (not including index date)
(Appendix A, DCLASS= “S_BBC”, “S_BBM”)
Exclude patients with >1 of any beta blocker prescription
on the index date (Appendix A, DCLASS= “S_BBC”,
“S_BBM”, “NS_BBL”)

Project Time Frame Definitions

April 1, 2002 to September 30, 2014
Accrual Start/End
Dates
March 31, 2015
Max Follow-up Date
When does observation First instance of any of the following events:
1. Death
window terminate?
2. 180 days of follow-up
3. March 31, 2015
Lookback Window(s) Do not include index date in lookback
 Comorbid conditions: 2 years
 Health care access: 1 year
 Baseline medications: 1 year

 Variable Definitions (add additional rows as needed)
Main Exposure or Risk Beta blocker dialyzability
Factor
 Exposed group: patients prescribed carvedilol (low
dialyzability) (Appendix A, DCLASS = “S_BBC”)
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Variable Definitions (add additional rows as needed)
 Control group: patients prescribed metoprolol (high
dialyzability) (Appendix A, DCLASS = “S_BBM”)

Primary Outcome
Definition
Secondary Outcome
Definition(s)

Look forward 180 days following index date (not including
index date) for:
 All-cause mortality (Appendix C)
Look forward 180 days following index date (not including
index date) for:
 Myocardial infarction
 Heart failure
 Ventricular arrhythmia

See Appendix C for outcome codes
Baseline Characteristics See Appendix E for baseline codes and Appendix F for full
baseline table
Other Variables

 Analysis Plan and Dummy Tables (expand/modify as needed)
Descriptive Tables (insert or append dummy tables), e.g.:
Table 1. Baseline characteristics according to primary/secondary exposure
Table 2. Outcomes according to primary/secondary exposure
Table 3. Covariates (baseline characteristics) according to outcomes
Statistical Model(s)
Type of model
Primary independent
variable
Dependent variable
Covariates
Sensitivity Analyses
Type of model
Primary independent
variable
Dependent variable
Covariates

See Appendix D for Output tables
1. Cohort selection (Table 1)
a. Report the number of patients in cohort overall, and for each drug
group
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2. Total event rate (Table 2)
a. Report the total number of events overall
Stop here for discussion
3. Baseline characteristics (Table 3)
a. Report baseline characteristics prior to propensity matching
b. Calculate the standardized difference between the two study groups: 1)
Exposed: carvedilol (DCLASS= “S_BBC”) and 2) Unexposed:
metoprolol (DCLASS= “S_BBM”)
Stop here for discussion
4. Primary analysis: Propensity scores
a. Propensity scores: calculate propensity score based on all baseline
characteristics below. Also report the probability (0 to 1) for pre- and
post-weight
(Note: The propensity score is the probability of exposure (E) conditional on the
covariates (baseline characteristics). This score involves a logistic model that estimates
the probability of being started on a specific anti-depressant, given these covariates.
Thus, patients with similar calculated probabilities will be compared to each other, in an
effort to eliminate bias.)
Include the following variables in the derivation of the propensity score using a
multivariable logistic regression model:














Sex (female* vs. male) – predictor of mortality
Age (in years, continuous variable) – predictor of mortality
Abdominal aortic aneurysm (yes vs. no*) – predictor of mortality, probably
Coronary artery disease (yes vs. no*) – predictor of mortality
Heart failure (yes vs. no*) – predictor of mortality, requirement for carvedilol
(true confounder)
Peripheral vascular disease (yes vs. no*) -– predictor of mortality
Stroke (yes vs. no*) – predictor of mortality
Use of ACE inhibitors (yes vs. no*) – predictor of mortality, requirement for
carvedilol (true confounder)
Use of alpha blockers (yes vs. no*) – measure of HTN, predictor of mortality
Use of ARBs (yes vs. no*) - predictor of mortality, requirement for carvedilol
(true confounder)
Use of calcium channel blockers (yes vs. no*) - measure of HTN, predictor of
mortality
Use of diabetes drugs (yes vs. no*) – predictor of mortality
Use of digoxin (yes vs. no*) - predictor of mortality, requirement for
carvedilol (true confounder)
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Use of nitrates (yes vs. no*)
Cardiologist visit (yes vs. no*) – requirement for carvedilol
Coronary revascularization (yes vs. no*)
Echocardiogram (yes vs. no*) – requirement for carvedilol
Comorbidity score (continuous) – predictor of mortality
b. Baselines: Report baseline characteristics after matching and
standardized differences (Table 4)
- Calculate the standardized difference between the two study
groups: 1) Exposed: carvedilol (DCLASS= “S_BBC”) and 2)
Unexposed: metoprolol (DCLASS= “S_BBM”)
c. Events: Determine aggregate event rates for all outcomes after
matching according to each study group: 1) Exposed: carvedilol
(DCLASS= “S_BBC”) and 2) Unexposed: metoprolol (DCLASS=
“S_BBM”) (Table 5)

Hard & Propensity Score Matching
We will use greedy matching with specified caliper width of ± 0.2 x the standard
deviation of the logit of the propensity score
 Austin, 2010 showed that the above caliper width results in optimal estimation of
difference in the risk
 Since we have a specified caliper width, the difference in the logit of the
propensity score between exposed and unexposed patients in the matched set is
required to be less than the pre-specified maximum caliper width
We will match without replacement
 Since we are matching without replacement, matched unexposed patients can no
longer serve as a candidate for being matched to another exposed patient
Matching Ratio: We will match 1 exposed patient with 2 unexposed patients on:
 The logit of the propensity score
 Age ± 2 years
 Sex
Stop here for discussion
Note: If we lose >80% of carvedilol patients through matching, then will switch to
propensity weighting
d. Regression (Table 6): Using the matched cohort from above, report
the absolute risk difference, odds ratio and 95% confidence interval by
performing conditional logistic regression analyses for all outcomes
using the exposed (DCLASS = “S_BBC”) and unexposed (DCLASS=
“S_BBM”, referent) study groups (Note: since outcomes are rare we
can approximate risk ratios from odds ratios)
Stop here for discussion

126



Additional analysis: TBD

 Quality Assurance Activities
RAE Directory of SAS
Programs
The final analytic dataset for each cohort includes all the
RAE Directory of Final
data required to create the baseline tables and run all the
Dataset(s)
models. It should include all covariates for all models
such as patient risk factors, hospital characteristics,
physician characteristics, exposure measures (continuous,
categorical) and outcomes. It should include covariates
that were considered but didn’t make the final cut. This
would permit an analyst to easily re-run the models in the
future.
RAE README file available:
☐Yes ☐No
Date results of quality assurance tools for final dataset shared
with project team (where applicable):
yyyy-mon-dd
%assign
yyyy-mon-dd
%evolution
yyyy-mon-dd
%dinexplore
yyyy-mon-dd
%track / %exclude
yyyy-mon-dd
%codebook
Additional comments:
Appendix A – Drug List
CarvedilolDrugList16
0201.xlsx

Appendix B – Cohort build

Appendix C – Outcomes

Appendix D – Output tables
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CarvedilolOutputTabl
es160205.xlsx

Appendix E – Baseline codes

Appendix F – Baseline table
Assume below unless stated:
CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Include suspected/questionable diagnoses?
No
OHIP:
Claim Type
NONLAB
NACRS
Source
Emergency Department visits
Include planned visits
No
Characteristic
Demographics
Age

Sex
Rurality

Socioeconomic

Code Set

Datasets Used

Other Details

RPDB

Report as mean,
SD, median, 25th,
75h percentiles,
and N (%) in
categories (66-69,
70-74, 75-79, 8084, 85-89, ≥90)
N (%) female
N (%) rural

RPDB
PSTLYEAR
Macro: %GETDEMO
Var name: RURAL
PSTLYEAR

Report as quintiles
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Status –
Neighbourhood
Income Quintile

Macro: %GETDEMO
Var:name: INCQUINT

(1, 2, 3, 4, 5, or
missing)
Income quintiles
using average
neighbourhood
income on index
date as defined by
Statistics Canada

1 is lowest quintile
(poorest) and 5 is
highest quintile
(richest)
Year of index
Report as N (%) in
event (2002categories: 2002,
2014)
2003, 2004, 2005,
2006, 2007, 2008,
2009, 2010, 2011,
2012, 2013, 2014
Comorbidities (5 year look back except Charlson and John Hopkins scores)
Abdominal
CIHI DAD
N (%) yes
aortic aneurysm
OHIP
Arrhythmia
CIHI DAD
N (%) yes
NACRS
OHIP
Chronic liver
CIHI DAD
N (%) yes
disease
NACRS
Chronic lung
CIHI DAD
N (%) yes
disease
NACRS
OHIP
Coronary artery
CIHI DAD
N (%) yes
disease (without
OHIP
angina)
NACRS
Heart failure
CIHI DAD
N (%) yes
NACRS
Implantable
CIHI DAD
N (%) yes
defibrillator
OHIP
Kidney
CIHI DAD
N (%) yes
transplant
OHIP
Myocardial
CIHI-DAD
N (%) yes
infarction
Pacemaker
CIHI DAD
N (%) yes
OHIP
Peripheral
CIHI DAD
N (%) yes
vascular disease
NACRS
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Stroke
TIA
Charlson
comorbidity
score (2 year
lookback)

John Hopkins
comorbidity
score (2 year
look back)

CIHI DAD
NACRS
CIHI DAD
NACRS
CIHI DAD
1. Identify all acute DAD
records for patients in 2 years
prior (do not include index
date)
2. Use the %charlson macro and
collapse over IKN – read macro
definitions
3. Keep the ‘charl’ variable
(weighted sum of the above
indicators) and provide
frequency results
Use %getacg macro to create
Johns Hopkins ACG ADG
scores, based on ICD-9, ICD10-CA, OHIP codes

N (%) yes
N (%) yes
N (%):
0 or no
hospitalization
1 hospitalization
2 hospitalizations
3+ hospitalizations
And report as
Mean, SD,
Median, 25th &
75th percentiles
Report as mean,
SD, median, 25th
percentile, 75th
percentile
Report as 0-4, 5-9,
10-14, 15-19, ≥20,
missing scores
missing will be
included in the
category that
contains the
median value for
the ACG score

Medication use (1 year look back)
ACE inhibitor
BC_ACE
ODB
Amiodarone
BC_AMI
ODB
ARB
BC_ARB
ODB
Alpha blocker
BC_AAB
ODB
Calcium channel BC_CCB
ODB
blocker
Diabetes drugs
BC_DBT
ODB
Digoxin
BC_DIG
ODB
Nitrate
BC_NIT
ODB
Statins
BC_STA
ODB
Warfarin
BC_WAR
ODB
Health services utilization (1 year lookback)

N (%) yes
N (%) yes
N (%) yes
N (%) yes
N (%) yes
N (%) yes
N (%) yes
N (%) yes
N (%) yes
N (%) yes
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Cardiologist visit

OHIP

N (%) yes
Spec = “60”
(Cardiology)

Primary care
visit

OHIP

Count only one
claim per patient
per day.
N (%) yes
Report as 0-4, 5-9,
10-14, 15-19, 2024, 25-29, ≥30
visits in the
previous year
Spec = “00”
(Family practice
and general
practice)

Carotid
ultrasound
Coronary
angiogram
Coronary
revascularization
Hemodialysis
duration

CIHI DAD
OHIP
CIHI DAD
OHIP
CIHI DAD
OHIP
OHIP

Count only one
claim per patient
per day.
N (%) yes
N (%) yes
N (%) yes
Time from index
date back to the
date of
hemodialysis
initiation (days)
Initiation of
dialysis definition:
1. OHIP
feecode
R849 (if
multiple
R849s
exist, select
the most
recent)

131

OR (if R849 is not
found)
Earliest recorded
chronic
hemodialysis
feecode (H540,
H740, G325,
G326, G860,
G862, G863,
G866)

Echocardiogram
Holter
monitoring
Stress testing

CIHI DAD
OHIP
CIHI DAD
OHIP
CIHI DAD
OHIP

Report mean, SD,
median, 25th & 75th
percentile,
minimum,
maximum
N (%) yes
N (%) yes
N (%) yes
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